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Abstract
The cell cycle is a fundamental process of cell biology, and its progression is highly regulated.
A critical mode of regulation for proper advancement of the cell cycle is the activation of the
CDKs by the CDC25 family of dual specificity phosphatases. The CDC25 proteins are often
overexpressed or misregulated in cancer, resulting in dysregulated cell growth, genomic
instability and evasion of apoptosis. The oncogenic role of theCDC25 proteins has inspired over
two decades of drug discovery efforts to inhibit their enzymatic activity. Despite these efforts,
no therapeutic agents targeting family ofCDC25phosphatases emerged. In order to identify new
classes of CDC25B inhibitors, new approaches to target CDC25 are needed.
We have employed a novel approach to inhibit the CDC25 family member CDC25B by
targeting its interaction with its native substrate, the CDK2/Cyclin A complex. We used two
different methods, fragment-based drug discovery and “gray-box” high-throughput screening,
to identify inhibitors of the CDC25B-CDK2/Cyclin A protein-protein interaction. Using NMR-
based fragment based screening, we identified a small molecule ligand of the CDC25B catalytic
domain. We solved the co-crystal structure with this ligand bound to CDC25B, and used this
structure to developmore potent analogs.Wehave shown that fragment-derived compounds can
disrupt the CDC25B-CDK2/Cyclin A interaction and inhibit CDC25B catalytic activity. To our
knowledge, our inhibitor-bound crystal structure of CDC25B is the first crystal structure with
CDC25B bound to a small molecule ligand.
We have also developed several protein-protein interaction assays to quantify the
xv
interaction between CDC25B and CDK2/Cyclin A. We employed these assays in three high-
throughput screens to identify several classes of CDC25B-CDK2/Cyclin A protein-protein
interaction inhibitors.The inhibitorswe identifieddonot targetCDC25B,but disrupt theprotein-
protein interaction by targeting CDK2/Cyclin A. Importantly, we have developed a high quality
screening assay for the identification of CDC25B-CDK2/Cyclin A interaction inhibitors. This
assay will be useful for future drug discovery efforts targeting the CDC25B-CDK2/Cyclin A
interaction.
In summary, we have developed two new approaches to inhibit CDC25B. These results
pave the way towards the development of new chemical probes and potential therapeutic agents
targeting CDC25B.
1Chapter 1
Introduction
1.1 Abstract
The biology of the cell cycle and its regulation by the cyclin dependent kinases (CDKs) and the
cell division cycle 25 (CDC25) phosphatases has been studied for many years. The activation of
the CDKs by the CDC25 proteins is critical for proper advancement through the cell cycle and
regulates vital cell cycle checkpoints. Dysregulation of the CDKs in cancer by overexpression
or aberrant activation of the CDC25 proteins overcomes cell cycle checkpoints, resulting in
unregulated cell growth, genomic instability and evasion of apoptosis. For these reasons,
regulators of the cell cycle, including the CDC25 phosphatases, have been active targets of
inhibitor development for many years. Yet no therapeutic agents targeting any of the CDC25
proteins havemade it through clinical trials despite significant drug discovery efforts. Presented
here is a summary of the role of the CDKs and CDC25s in normal and cancer biology, as well
as previous efforts to inhibit the CDC25 phosphatases.
21.2 Structure and function of CDC25 phosphatases and their CDK/Cyclin substrates
1.2.1 CDK/Cyclin complexes in cell cycle regulation
The cyclin-dependent kinases (CDKs) are important regulators for progression through the cell
cycle. CDK family members regulate a wide variety of cellular processes including cell growth,
DNA replication and damage repair, and mitosis1–3. In humans, there are 13 genes encoding the
classical CDK family proteins CDKs 1-13, and an additional 9 genes encoding for proteins
identified to be CDK-like proteins based on sequence homology and conserved primary
structure4,5. All CDKs contain a Ser/Thr protein kinase domain that is responsible for its
enzymatic activity. The CDKs are highly similar across the family, with sequence identities
ranging from 40 – 60 %. CDK family members all have a fold common to all protein kinases
containing an active site with an ATP binding cleft between N-terminal and C-terminal lobes.
TheCDK family of kinases is highly conserved; of the 13 classical CDKs found in humans, there
are 11 homologs in D. melanogaster, 10 in C. elegans and a single CDK in S. cerevisiae6.
Complementation experiments highlight the degree of conservation by showing that the human
homolog of CDK1 can complement a mutated form of the S. cerevisiae CDK7.
Due to the regulatory role of the CDK family in many cellular processes, their activity
is highly regulated (Figure 1.1). A primarymode of regulation is through the binding of proteins
calledcyclins resulting in formationofcatalyticallyactiveCDK/Cyclinheterodimercomplexes8.
Cyclin binding to a CDK plays two roles in activating the CDK. First, cylins induce a
conformational shift in two regions of CDK that occlude the active site in the free form of the
CDK, allowing for substrate access to the active site9. Second, cyclins contain a binding site that
is responsible in part for substrate recruitment and the specificity of CDK activity through their
RxL-binding pocket10,11. CDKs are also regulated through phosphorylation. Activation of CDKs
3is achieved through phosphorylation of Thr160 by the CDK activating kinase (CAK) on the
conserved T-loop on CDKs which greatly increases the catalytic turnover rate12,13. Inhibitory
phosphorylation by Wee114 or Myt115 kinases on T14 and/or Y15 in the conserved P-loop of
CDK2 locks the active site in a closed conformation16. Removal of inhibitory phosphorylations
onT14and/orY15by the cell division cycle 25 (CDC25)phosphatases on the conservedglycine-
rich P-loop ofCDK further opens access to the active site and is required for full kinase activity17.
Importantly, dephosphorylation of the CDKs by the CDC25 phosphatases is thought to be the
rate-limiting step in CDK activation18,19. In addition to cyclin binding and phosphorylation state,
it has recently been shown that, at least for the CDK2/Cyclin A complex, intracellularMg2+ also
plays a role in tuning CDK activity20,21.
The various roles for the different CDKs in the phases of the cell cycle have been studied
for many years. Canonically, CDK4 and CDK6 are activated by D-cyclins (D1, D2, D3) in G1
phase to promote progression of the G1 and early S phases primarily through phosphorylation
Figure 1.1. Steps in CDK activation. Schematic of how CDKs are regulated by cyclin binding
and phosphorylation state. Red “P” circles represent inhibitory phosphorylations and green “P”
circles represent activating phosphorylations. Enzymes responsible for catalyzing the
phosphorylation reactions are given.
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4of the retinoblastoma family proteins p107, p130, and pRb22,23. Phosphorylation and subsequent
activation of the retinoblastoma family members leads to the expression of E-type cyclins (E1,
E2), which in turn bind and activate the CDK2 protein early in S-phase to initiate DNA
synthesis6,23,24. Once S-phase is initiated, E-type cyclins are actively degraded and replaced by
A-type cyclins for CDK2 binding4,25. The CDK2/Cyclin A complex regulates the S-G2 phase
transition through the phosphorylation of a variety of proteins including transcription factors and
cell-cycle checkpoint proteins26,27. In the early stages of mitosis A-type cyclins interact with
CDK1 to stop DNA replication and to control the spindle assembly process3,28. A-type cyclins
are then degraded and CDK1 binds to B-type cyclins, which regulate many mitotic processes
such as chromosomal condensation29,30.
Recent genetic studies usingCDKknockouts inmice has cast somedoubt on the classical
role of the CDKs. In mouse models, CDK1 knockout is the only CDK family member that is
absolutely required for cell division31. Knockouts of other CDKs, alone or in combination, are
either embryonic lethal or lead to sterile adult mice but do not show unilateral cell cycle arrest4.
This suggests a compensatory role for CDK1 throughout all phases of the cell cycle. Roles for
the other CDK familymembersmay bemore tissue specific, asmicewithout CDK2, CDK4, and
CDK6 are embryonic lethal due to decreased hematopoietic precursors31.
1.2.2 Structure and biology of the CDC25 phosphatases
As mentioned above, the CDC25 family of phosphatases are critical regulators of the CDK
proteins by catalyzing the removal of inhibitory phosphates. The CDC25 phosphatases are dual
specificity phosphatases belonging to the protein tyrosine phosphatase superfamily of
enzymes32, which are characterized by their phosphatase activity through a signature HCX5R
5catalytic motif. There are three genes encoding for the CDC25 phosphatases in humans
corresponding to the three CDC25 family members, CDC25A, CDC25B, and CDC25C32. All
three CDC25 family members contain an N-terminal regulatory domain and a C-terminal
catalytic domain. The regulatory domains of the family members vary widely between the three
proteins, and alternative splicing in the N-terminal domains leads to multiple isoforms for each
protein33,34. TheN-terminal domainof theCDC25proteins contains a both anuclear export signal
(NES) and a nuclear localization signal (NLS), as well as many phosphorylation sites involved
in their regulation. The C-terminal catalytic domains are highly similar between all three
proteins, with approximately 60 % sequence identity between any of the family members. The
three phosphatases have highly similar protein folds, the only exception being an additional C-
terminal helix found in the CDC25B crystal structure that is not observed the crystal structures
of either CDC25A or CDC25C35–37. Other than their active site HCX5Rmotif, the CDC25 family
is distinct from all other known protein tyrosine phosphatases in both sequence homology and
protein fold32. Potentially due to their unique structures, the CDC25 proteins are the only known
phosphatases to catalyze removal of the inhibitory CDK phosphorylations32. Additionally, only
a few non-CDK substrates have been identified38,39, indicating that their primary role in the cell
is to activate CDK proteins.
The CDC25 phosphatases have been thought to play specific roles throughout the cell
cycle (Figure1.2).CDC25Ais considered tobe theprimary regulator in theG1/Sphase transition
by dephosphorylating and activating the CDK4/6/Cyclin D, CDK2/Cyclin E and CDK2/Cyclin
A complexes40–42. The S/G2 phase transition checkpoint is dominantly regulated by CDC25B43.
CDC25B regulates this checkpoint by dephosphorylation and activation of both the CDK2/
Cyclin A and CDK1/Cyclin B complexes44. Interestingly, of all three CDC25 family members,
6CDC25B is required for resumption of the cell cycle after DNAdamage45. All three CDC25s are
thought to promote mitosis by dephosphorylating CDK1/Cyclin A and CDK1/Cyclin B46,47.
Contrary to the idea of delineated roles for the individual CDC25 family members, some
functional redundancy has been observed46,48,49. For example, mice lacking CDC25B and
CDC25C are sterile but develop normally, demonstrating that CDC25A can perform all the
functions required for proper cell division50.
Given their critical role in the cell cycle, CDC25 phosphatases are subject to tight
regulation from a variety of signaling pathways. CDC25 proteins are regulated throughmultiple
mechanisms, including phosphorylation state51,52, differential expression53,54, subcellular
Cyclin D
CDK4/6
M
G1
G2
S
Cyclin E
CDK2
Cyclin A
CDK2
Cyclin A
CDK1
Cyclin B
CDK1
CDC25B
CDC25A
CDC25C
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Figure 1.2 Roles for the CDKs and CDC25s in cell cycle progression. Schematic of how the
different CDK/Cyclin complexes regulate the phases of the cell cycle. A circle representation of
the cell cycle is surrounded by the CDKs and their cyclin binding partners that are active in the
cell cycle phase to which they are adjacent. The CDC25s responsible for the regulation of the
various CDKs are shown with arrows pointing toward their substrates.
7localization55,56, and degradation57,58. CDC25A is primarily expressed in G1 phase and is
ubiquitinylatedanddegradedafter the completionofmitosis41,57.CDC25B is expressedprimarily
during S phase, and after the G2/M phase transition it is rapidly degraded59,60. The role of
CDC25C appears to be primarily related to meiotic cell division61,62, but reports have also
indicated that it may have a function in both S and G2/M phases49,63. In addition to regulation by
transcription and degradation, phosphorylation of CDC25 proteins also regulates their function
throughout the cell cycle. Importantly, phosphorylation by CDK/Cyclin complexes creates
feedback loops to promote cell cycle advancement. For example, phosphorylation of CDC25A
byCDK2/Cyclin E in theG1/S phase transition increases its activity64, which in further activates
CDK2 leading to signal amplification and promotion of DNA synthesis. Conversely,
phosphorylation ofCDC25BbyCDK1/CyclinB induces the degradation ofCDC25Bduring the
progressionofmitosis65. In addition to the roleofphosphorylationof theCDC25s throughnormal
cell division, regulation byphosphorylation is a criticalmechanism for the induction of cell cycle
arrest upon DNA damage. The CDC25s are substrates for Chk1 phosphorylation66, a critical
kinase in theDNAdamage responsepathway.PhosphorylationbyChk1 leads to theproteasome-
mediated degradation or cytoplasmic sequestration of the CDC25 proteins67,68. Loss of the
CDC25 phosphatases by either mechanism results in cell cycle arrest, which allows the cell to
repair the damaged DNA before reentry into the cell cycle45 or to induce apoptotic pathways69.
This response is critical for the maintenance of genomic stability.
1.2.3 Recognition and activation of the CDK2/Cyclin A complex by CDC25B
Activation of the CDK2/Cyclin A complex by CDC25B is a critical step in late S phase to
complete proper DNA synthesis and start the mitotic process. The molecular mechanisms
8responsible for mediating the interaction between CDC25B and CDK2/Cyclin A have been
probed by structural analysis70, computational modeling71, mutagenesis72,73 and enzyme
kinetics74. As mentioned above, the active site of CDC25 phosphatases is shallow compared to
other protein tyrosine phosphatases, and phospho-peptides are poor substrates regardless of
peptide sequence75. Compared to phospho-peptide substrates, the catalytic rate of CDC25B for
its native substrate pT14pY15-CDK2/Cyclin A is approximately six-orders of magnitude
faster75. These experiments suggest that the mode of substrate recognition occurs through
alternative sites and not through the active site. Additionally, full length CDC25B protein and
CDC25B protein containing just the C-terminal catalytic domain have similar activities towards
pT14pY15-CDK2/Cyclin A, indicating that all essential interaction motifs for substrate
recognition are present within the catalytic domain of CDC25B70.
Though the structure of the CDC25B-CDK2/Cyclin A complex is not known,
computationalmodels of the interaction and subsequentmutagenesis have demonstrated that the
protein-protein interaction is mediated primarily through two regions on CDC25B71,72,76 (Figure
1.3). The first region is a so-called protein-protein interaction “hotspot”, which is distant from
Figure 1.3 Model of the CDC25B-
CDK2/Cyclin A interaction based on
computational and mutational
studies. Model of the PPI based on
studies by Sohn et al.72 CDC25B,
CDK2, and Cyclin A are shown in
gray, yellow, and purple respectively.
The C-terminal region of CDC25B is
indicated as a dark gray line. The
region near the CDC25B active site is
labeled and colored red. The PPI sites
are also labeled, and the PPI “hotspot”
region is colored green.
CDC25B
C-terminus
Active site
"Hotspot" PPI site
2nd PPI site
CDC25B
CDK2
Cyclin A
9the active site. Mutations in this site, specifically residues R488, R492, and Y497, are highly
detrimental to enzymatic activity of CDC25B towards pT14pY15-CDK2/Cyclin A, but do not
affect activity toward artificial substrates71,72,76. For example, mutation of R492 to leucine
decreases the phosphatase activity of CDC25B over 100-fold in vitro, and closely resembles the
activityof acatalytically inactivemutant invivo72.Similarly,mutationof twoaspartic acidsD206
and D210 on CDK2 also decreases the rate of dephosphorylation by CDC25B72. Double mutant
cycles have shown that that swapping of charged residues in these sites is less detrimental than
milder hotspotmutations72, indicating that potentially these two sitesmaydirectly interact to help
mediate substrate recognition. Besides this protein-protein hotspot interaction, a second region
of CDC25B also helps in substrate recognition. Deletion of the 17 C-terminal residues of
CDC25B decreases the pT14pY15-CDK2/Cyclin A dephosphorylation rate 10-fold73. Specific
mutation of R556 and R562 to leucines shows a similar dephosphorylation rate as observed for
the truncated protein, indicating that these residues are responsible for the majority of the
catalytic benefit gained from the C-terminus73. The binding site of the CDC25B C-terminus on
the CDK2/Cyclin A complex is unknown.
1.3 Role of CDC25 phosphatases in cancer
Due to their regulation of cell cycle checkpoints and their role in the DNA damage response, it
is not surprising that the CDC25 phosphatases have been shown to play a role in cancer.
Overexpression of CDC25 phosphatases is observed in a wide variety of human cancers,
including ovarian77, breast78, liver79, prostate80, colorectal81, gastric82, thyroid83,84, glioma85, head
and neck cancers86, and non-Hodgkin lymphoma87. No reports of gene amplification or
rearrangements have been reported, so the mechanism of overexpression is not entirely clear. It
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has been shown for several cancers that CDC25 overexpression is due to increased CDC25
transcription from upstream oncogenic transcription factors such as Myc53 or E2F54. In other
cancers, CDC25 overexpression occurs through stabilization at the protein level through a
suppression of degradation pathways88. No matter the mechanism, overexpression of CDC25A
and/orCDC25Boften correlateswith higher tumor grades,metastatic disease, and subsequently,
poor patient outcomes in many cancers77,79,84,85,89–92.
The CDC25 phosphatases, primarily CDC25A and CDC25B, have been shown to play
a role in both tumorigenesis and tumor progression. Overexpression of CDC25A or CDC25B in
mouse mammary glands induces hyperplasia, but overexpression alone was not sufficient for
oncogenesis93,94. However, in the context of either RAS or Neu overexpression, tumor-free
survival in mice was almost half that of RAS or Neu overexpression alone94. Additionally,
overexpression of CDC25B decreased mouse mammary tumor latency upon exposure to the
carcinogen DMBA (7,12-dimethyl-1,2-benzanthracine)95. This indicates that CDC25A and
CDC25Bmaybe rate-limiting factors inRASorNeu-driven oncogenesis in breast cancermouse
models96. In addition to tumor initiation, theCDC25proteins play a role in tumor progression and
maintenance. First, CDC25 proteins are downstream targets of cell growth signaling pathways,
and link these pathways to cell cycle regulation97–99. In cancer, the constitutive expression of
CDC25s promotes unregulated promotion of the cell cycle and cellular proliferation. A second
critical oncogenic effect of CDC25 overexpression is the loss of DNA damage checkpoints. As
outlined above, upon DNA damage CDC25 proteins are inactivated through degradation or
sequestration to the cytoplasm in order to arrest the cell cycle and allow for the DNA damage to
be repaired or for the induction of apoptosis. CDC25 overexpression circumnavigates the DNA
damage checkpoints, promoting genomic instability100,101. For example, studies found that cells
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in which CDC25B is overexpressed enter mitosis whether or not their DNA replication was
complete47. In a second study, it was shown that cells with higher levels of CDC25A due to an
inactive Chk2mutation continuedDNA synthesis despite exposure to ionizing radiation102. This
insensitivity to regulatory pathways is possibly due to the increased CDC25 protein levels
overwhelming the degradative or sequestration regulation mechanisms. Through several
mechanisms, the involvement of the CDC25 phosphatases in cancer has indicated their
therapeutic value.
1.4 Previous drug discovery efforts targeting CDC25 phosphatases
1.4.1 CDC25 phosphatases as potential anti-cancer drug targets
The CDC25 phosphatases have been considered attractive therapeutic targets for many reasons.
Genetic experiments using siRNAor knockdownmodels suggest that the inhibition ofmembers
of theCDC25 family can slowor arrest tumor cell growth both in vitro and in vivo103–106. Inmouse
mammary tumor models, heterozygous knockout of CDC25A significantly delays tumor
initiation upon expression of RAS or Neu103. Transcriptional repression of CDC25B in acute
myeloid leukemia or expression of miRNAs targeting CDC25B in pancreatic ductal
adenocarcinoma cells blocks the ability of these cells to form colonies in soft agar104,105. In
hepatocellular carcinoma cell lines, suppression of CDC25B expression by siRNA induces cell
cycle arrest in late S and G2 cell cycle phases, reduces growth rate, and reduces invasion and
migration potential106. These cells, when subcutaneously injected into mice have a marked
reduction in the rate of tumor growth106. Although studies have demonstrated that CDC25A is
sufficient to drive the cell cycle in developing mice50, these experimental results indicate that
cancer cell growth can be dependent on either CDC25A or CDC25B overexpression.
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Importantly for thedevelopment ofCDC25 inhibitors, targeting the cell cycle has already
been shown to be a viable therapeutic approach in cancer. Indeed, several cell cycle inhibitors
have already shown promise in clinical trials107,108. The majority of current therapeutic agents
specifically targeting the cell cycle are CDK inhibitors109–111. Though some efficacy has been
shown for CDK inhibitors as single agents109,112, combinations with chemotoxic agents such as
letrozole113 and mitoxantrone114 have shown promise in phase 2 clinical trials. Approved in
February 2015, theCDK4/6 inhibitor Palbociclib is the first CDK inhibitor to be approved by the
FDA115.Despite this success,manyclinical trials usingCDKinhibitors have shown limited effect
and significant toxicity116–118. These studies indicate that while inhibition of the cell cycle is a
viable approach for cancer therapies, inhibitors with new mechanisms of action are needed.
1.4.2 Previous identification and characterization of CDC25 inhibitors
Due to their therapeutic value, the CDC25 phosphatases have been the target of drug discovery
efforts forover twentyyears119,120. Primarily, twoapproacheshavebeenused to identify inhibitors
of CDC25s. The first approach is the identification of natural product inhibitors, such as the
dysidiolides and naturally occurring quinone containing compounds like vitamin K3121–124
(Figure 1.4). The natural product inhibitors and their derivatives inhibited CDC25 phosphatases
with potencies in the low to mid micro-molar range122,123,125; however, studies later showed that
many of these compounds were either non-specific for the CDC25s compared to other protein
tyrosine phosphatases126,127 or were less potent than first reported upon retesting128. Despite the
non-specificity of the natural products and their derivatives, several have been tested and found
to be active in cancer cell lines129,130.
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The second major approach to CDC25 inhibitor identification, comprising the majority
of drug discovery efforts, has been high-throughput screening targeting CDC25 enzymatic
activity.All high-throughput screening studies to date have employed adephosphorylation assay
using an artificial substrate as a readout for CDC25 activity131–135. Using these high-throughput
screening approaches, several lead compounds have emerged. The most successful of these
compounds have been the quinone-containing class (Figure 1.4). Though these compounds have
been extensively studied, their mechanisms of action are still not clear. Studies have indicated
that quinone-containing compounds can inhibit the CDC25 phosphatases by covalent
modification131 or oxidation of the active site cysteine136, thereby inhibiting enzymatic activity.
This is evidenced by the fact that many of these compounds have been shown to increase
intracellular reactive oxygen species, and lose activity in vitro upon the addition of a reducing
agent such as DTT135–137. A potent bis-quinone compound IRC-083864138 under the name Debio
0931 entered phase II clinical trials in 2009, but no data has yet been released. In all, more than
40 patents exist for CDC25 inhibitors spanning over 20 years of drug discovery efforts119,120, yet
no therapies targeting CDC25 phosphatase are currently available in the clinic.
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IRC-083864 (Debio 0931)
NBr
O
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Figure 1.4. Previously identified
inhibitors of the CDC25 phosphatases.
Structures of several published inhibitors
of the CDC25 family. The top three
compounds are representative of inhibitor
classes derived from natural
products122,125,148. The bottom two
compounds are representative synthetic
inhibitors from the quinone class of
compounds138,149. IC50 for CDC25B
inhibition in vitro are shown.
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1.5 Rationale for the development of new approaches to target CDC25 phosphatases
TheCDC25 phosphatases have been validated to be of therapeutic value in cancer, and represent
an alternative approach to inhibit the cell cycle. Additionally, their unique structure and
biological function compared to other protein tyrosine phosphatases may allow for the
development of selective inhibitors.
As detailed above, previous drug discovery efforts targeting the CDC25s have had not
yet lead to any successful clinical candidates. The promiscuity of many natural product and
synthetic inhibitors has made them unattractive due to potential off-target effects. Additionally,
several of the current CDC25 inhibitors are reactive quinone-containing compounds or
generators of reactiveoxygen species, including the clinical candidate IRC-083864.Asquinones
have been affiliated with toxicity139 and increased levels of reactive oxygen species are
considered to play an oncogenic role in tumor biology140,141, inhibiting CDC25 with such
compounds may not be the best strategy.
The identification of reactive and non-specific inhibitors is in part due to the inherent
drawbacks of previous methods used to identify CDC25 inhibitors. As mentioned above, the
majority of screening approaches employed artificial substrates as readouts for inhibition of
enzymatic activity. These substrates have at least two orders of magnitude slower reaction rates
than are observed for the native pT14pY15-CDK2/CyclinAsubstrate75. In addition to beingpoor
substrates, screening with such reagents only targets the CDC25 active site. As outlined above,
theCDC25active site is shallow, confers no substrate recognition, and is theonly structuralmotif
in the CDC25s that is conserved with other protein tyrosine phosphatases. Given the nature of
the CDC25 active site, it is unlikely that screening approaches targeting this site would yield
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selective inhibitors. In addition, no structural or biophysical characterization for any of the
previously identified inhibitors has been published, leaving their complete mechanism of action
unclear.
For these reasons, we proposed to inhibit CDC25B by blocking its interaction with
CDK2/Cyclin A. As opposed to previous studies, we employed biophysical and chemical
biology approaches to identify and characterize CDC25B inhibitors. Additionally, instead of
using artificial substrates to identify CDC25B inhibitors our studies focused on using a
biologically relevant substrate, the CDK2/Cyclin A complex. The proposed approach of
targeting the CDC25B-CDK2/Cyclin A protein-protein interaction has two primary advantages
over previous attempts to identify CDC25B inhibitors. First, targeting the CDC25B-CDK2/
Cyclin A protein-protein interaction instead of CDC25B catalytic activity addresses the bias
towards targeting the shallow active site of CDC25B that is inherent in all previous inhibitor
discovery efforts. Inhibitors identified using this approach do not target a specific binding site
and can bind to any site on CDC25B or the CDK2/Cyclin A complex responsible for mediating
the protein-protein interaction. Second, this approach is much less sensitive to oxidizing agents
such as the quinone-containing class of CDC25B inhibitors. As stated above, many previously
identified compounds inhibit CDC25B activity by oxidizing the catalytic cysteine of CDC25B
through the generation of intracellular reactive oxygen species. By screening for inhibitors of the
CDC25B-CDK2/Cyclin A protein-protein interaction instead of CDC25B catalytic activity
inhibitors, the bias of previous screens towards the identification of oxidizing agents is removed.
This is important because many of the CDC25B inhibitors that are active through oxidation of
the catalytic cysteine are from the quinone-containing class of compounds, which have been
associated with toxicity in vivo139.
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In addition to the advantages of targeting the CDC25B-CDK2/Cyclin A interaction,
inhibitors identified using this approach may have advantages over previously characterized
CDC25B inhibitors. One of the limiting factors of previously described CDC25B has been their
toxicity, likely caused by their non-specific reactivity or their generation of intracellular reactive
oxygen species.Due to the removal of thebias towards the identificationof inhibitors that oxidize
the highly reactive CDC25B catalytic cysteine, inhibitors identified by targeting the CDC25B-
CDK2/Cyclin A protein-protein interaction may be less likely to be oxidizing agents.
Identificationof compoundswith amechanismof inhibitionother thanoxidationof theCDC25B
catalytic cysteine may be less toxic than previously identified inhibitors.
In addition to limiting the toxicity of CDC25B inhibitors by targeting the CDC25B-
CDK2/Cyclin A interaction instead of CDC25B catalytic activity, inhibitors of the protein-
protein interactionmayexhibit increased specificity forCDC25B.Asdescribedabove, the active
sites of the CDC25 family members are the only structural motifs shared with all other protein
phosphatases and are very shallow compared to other protein phosphatases. For this reason it is
unlikely that compounds targeting the active sites of the CDC25 family could be highly specific.
However, the rest of the structure of the CDC25 familymembers is unique compared to all other
protein phosphatases. Therefore targeting sites other than the active site on CDC25B may
represent a better approach towards the development of specific CDC25B inhibitors. A specific
inhibitor of CDC25B or an inhibitor specific to the CDC25 family would be a useful tool for
understanding the biology of these important phosphatases, as well as potentially being useful
for more targeted therapies.
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Notes
Many of the topics presented here have been well reviewed and deserve acknowledgment.
The roles of the CDKs in normal and cancer biology have been well described by Malumbres
et al6; the role of the CDC25 family in cancer and their value as therapeutic targets has been
reviewed by Buotros et al.142,143, Kiyokawa et al.144, Rudolph145, and Lazo146; the structure and
function of the CDC25 phosphatases has been reviewed by Rudolph147; patent reviews of
CDC25 inhibitors have been written by Lavecchia et al.119,120.
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Chapter 2
Characterization of CDC25B-CDK2/CycA-Mre11 interactions using biochemical and
biophysical methods
2.1 Abstract
ActivationofCDK/Cyclin complexes is a critical step incell cycleprogression, and their aberrant
regulation occurs in many cancers. The CDC25B phosphatase is a critical regulator of CDK2/
Cyclin A and has been validated as an important therapeutic target in cancer. Recently the DNA
double strand break repair protein Mre11 has also been shown to interact directly with CDK2/
Cyclin A, leading to its activation. Characterization of these proteins and their molecular
interactions is critical for understanding CDK2/Cyclin A biology as well as for the development
of chemical probes to inhibit aberrant regulation of this complex. Here we show that CDC25B
is rigid in solution and its structure closelymatches that found in the crystal structure. In addition,
we have characterized the CDC25B-CDK2/Cyclin A interaction using a variety of biophysical
techniques and found that CDC25B makes multiple contacts with CDK2/Cyclin A. Finally, we
determined the bindingmode betweenCDK2/CyclinA and the activatorMre11, finding that the
interaction is mediated by twomotifs on theMre11 C-terminus and interacts with CDK2/Cyclin
A at least in part through contacts to the RxL peptide binding pocket on Cyclin A. These results
lead to new understandings of how CDK2/Cyclin A is regulated and has implications for the
development of chemical probes and potential therapeutics targeting its activation.
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2.2 Introduction
Asdiscussed inChapter 1, theCDC25dual-specificity phosphatases are key regulators of the cell
cycle. Their oncogenic role in cancer has led to their active targeting for smallmolecule inhibitor
development1–4. Because of their potential as therapeutic targets in cancer, studies of CDC25
family catalytic mechanism and structure are of vital importance.
Previous molecular dynamics simulations combined with bioinformatics analysis have
suggested that approximately 20 C-terminal residues of CDC25B are partially unfolded or
disordered in solution5,6. It has been hypothesized that dynamics of the C-terminus allows for the
formation of transient pockets near the active site5,6. If confirmed, these results would have
important implications for the development of any CDC25B inhibitors through structure-based
drug design6. Therefore, the need for experimental characterization of the dynamics of CDC25B
has been emphasized in the literature6.
Themostwell studiedbiological role forCDC25Bis thedephosphorylationof theCDK2/
Cyclin A7–10. A variety of experiments addressing this interaction using biochemical and
enzymatic methods resulted in an understanding of how CDC25B catalyzes the
dephosphorylation reaction8, and has provided insight on the interaction mechanism through
mutagenesis and computational modeling7,9,10. However, direct biophysical characterization of
the interaction in solution has not been done. Understanding this interaction is critical for the
development of small molecule inhibitors targeting the protein-protein interaction. For this
reason, we assessed the CDC25B-CDK2/Cyclin A interaction in a variety of biophysical
experiments.
In addition to its interaction with CDC25B, the CDK2/Cyclin A complex has several
other binding partners that regulate its activity. One such recently identified binding partners is
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the DNA damage response protein Mre1111. Mre11 plays a critical role in DNA double strand
break repair, canonically through its role in theMRNcomplex (Mre11,Rad50, andNBS1)12. The
MRN complex is involved with both the homologous recombination13 and the non-homologous
end joining14 mechanisms of double strand break repair through its interaction with the ends of
DNAdouble strand breaks15, its end resection at breaks16, aswell as its recruitment and activation
of ATM to initiate DNAdamage signaling17. AnMRN-independent role forMre11 has emerged
in cell cycle regulation through activation of CDK2/Cyclin A. Recent studies by Buis et al. have
demonstrated that a direct interactionbetweenMre11 and theCDK2/CyclinAcomplex links cell
cycle regulation andDNAdouble strandbreak repairmachinery to restrict theuseof homologous
recombination S and G2 phases11. They determined the interaction between Mre11 and CDK2/
CyclinAregulates thephosphorylation state andprotein levels ofCtIP, a critical protein involved
in the homologous recombination pathway of DNA double strand break repair18. The
phosphorylation state of CtIP was found to be dependent on the kinase activity of CDK2.
Increased phosphorylation of CtIP resulted in higher CtIP protein levels through a reduction in
proteasome-mediated degradation. Buis and colleagues also determined through yeast two
hybrid experiments that Mre11 interacts directly with the CDK2/Cyclin A complex, with a
minimal interaction motif in the very C-terminal region of Mre11. Beyond this, little is known
about the mechanism of the Mre11-CDK2/Cyclin A interaction. To better understand the
mechanism of this interaction, we studied the Mre11-CDK2/Cyclin A interaction in vitro.
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2.3 Dynamics of the CDC25B catalytic domain in solution
In order to probe the backbone dynamics of the catalytic domain of CDC25B by NMR, we
assigned theCDC25Bbackboneusing triple resonance experiments.Our initial studies indicated
that CDC25B was well folded, due to the good peak dispersion on the 1H15N-HSQC spectrum.
However, we observed that the wild-type protein was unstable in solution over longer periods of
time, leading to reduced quality of theNMRspectra.We found that a pointmutation of the active
site cysteine to serine (C473S) drastically improved the long-term protein stability, most likely
due to reducingproteinoxidationat this residue. Inorder to ensure that thismutationdidnot affect
the structure or backbone dynamics of CDC25B, we measured the 1H15N-HSQC spectra
(Appendix Figure 2.A1) and the backbone 15N T1, T2 relaxation times (Appendix Figure 2.A2)
for both themutant and thewild-type proteins. These experiments indicate that thewild type and
C473S mutant proteins have nearly identical structures and backbone flexibility in solution.
Moreover, it has beenpreviously shown that the structure ofC473Smutant is identical to thewild
type protein10. Due to the increased long-term stability of the CDC25B C473S mutant, we
selected this variant for characterization using solution NMR.
The 1H-15N HSQC spectrum for the CDC25B C473S protein contains 155 resonances
peaks, which constitutes 83% of the expected resonances for all of the backbone amides present
in the sequence. Of these, we were able to assign 92 % of the observed backbone amide
resonances using triple resonance NMR experiments (Figure 2.1). The unobserved amide
resonances correspondprimarily to severalN-terminal residues aswell as residues located in two
loop regions, corresponding to residues 461-467, and 495-504. These regions most likely are
unobserved due tomotions of these residues and rapid exchange of the amide protonswithwater,
leading to peak broadening. This is in agreement with data from the published crystal structure
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of CDC25B, which has no electron density for the N-terminal residues unobserved byNMR and
highB-factors for those residues in the 495-504 loop region, indicating a lack of structure for this
region10.
To explore the protein backbone dynamics of the CDC25BC473S on the pico-second to
nano-second timescale, we measured the R1 and R2 relaxation rates as well as the steady state
1H-15N heteronuclear NOE for the backbone amides using previously described methodology19.
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Figure 2.1. Assignment of CDC25B catalytic domain. A) The 1H15N-HSQC spectrum of the
CDC25B catalytic domain is shown with assignments labeled. Cutout of the overlapped region
denoted by the dotted box shown below.B)Cutout of the overlapped region of the spectrumwith
assignments.
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These experiments measure the loss of peak intensity at several different time intervals, and the
extent of this loss in peak intensity is indicative of backbone motion on the ps-ns timescale. We
then used Lipari-Szabo model-free analysis20 to assess these fast time-scale backbone motions
of CDC25B C473S. This analysis determined the global correlation time, a measure of the rate
of protein tumbling in solution, to be 11.4 µs. This correlation time is consistent with that
expected for a globular, monomeric protein of similar molecular weight to CDC25B.
Additionally, the model-free analysis approach produces a measure termed the order parameter
(S2) that quantitatively represents the overall order of a given amide in solution. The values of
the of the order parameter range from 0, corresponding to completely unrestricted motion of the
amide, to 1, which corresponds to an amide with no motion. This analysis yielded an average
order parameter of 0.94 across all the measured amides, which is indicative of a well ordered
Figure 2.2. The CDC25B catalytic domain is rigid in solution on the ps-ns timescale. The
generalized order parameter (S2) is shown for the entire sequence as determined by model free
analysis, with a box around C-terminal helix denoting the helix previously reported to be
dynamic. A schematic of CDC25B secondary structure is shown above.
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backbone with limited internal dynamic motion on the ps-ns timescale (Figure 2.2). Such a
relatively high averageorder parametermay result froma lackof peaks for several amides in loop
regions, again likely due to their fast exchange with water.
Only a few resonances showorder parameters of less than 0.85, and these are exclusively
found either at one of the CDC25 termini, or within the internal loop region 461-467. None of
the observed amides experience an S2of less than 0.7, indicating that no region of the assigned
protein, including the C-terminal helix, experiences any significant dynamics on this timescale.
The model-free analysis also indicates that several residues experience additional exchange
processes in the micro-second to milli-second timescale which contribute to the observed
relaxation data (Figure 2.3). With the exception of E450 and R488, the remaining residues
modeledwith Rexcontributions appear immediately adjacent to or within loop regions, and all of
the residues are further than 10 Å from the active site. To ensure the dynamics of CDC25B was
Figure 2.3. The CDC25B catalytic domain is rigid in solution on the ms timescale as calculated
by model-free analysis. Additional exchange processes (Rex) on the millisecond timescale as
predicted by model free analysis. A box around the C-terminal helix is shown.
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not altered by the C473Smutation, wemeasured both R1 andR2 relaxation rates for thewild type
protein (Appendix Figure 2.A2). Data obtained from these experiments are highly consistent
with the data recorded for the mutant, showing an average deviation of 0.048 s-1 and 1.57 s-1 for
R1 and R2 respectively.
To examine closer the possibility of conformational exchange within the CDC25B
C473S mutant catalytic domain on slower, µs-ms time scales, we carried out 15N relaxation
dispersion measurements using Carr–Purcell–Meiboom–Gill (CPMG) experiments21. These
experiments revealed that only a few residues experienced significant exchange on the μs-ms
timescale (Figure2.4).Similar to the relaxationdata acquired for shorter timescales, themajority
of these backbone amides experiencing dynamics were found within or adjacent to loop regions
(Figure2.4).Several residues formsmall clusters, for exampleL388-Q389-T390orD419-K420-
Figure 2.4. The CDC25B catalytic domain is rigid in solution on the ms timescale experimentally.
Left: representative relaxation dispersion plots for K420 and L453 with R2,eff shown as a function of
CPMG pulse frequency in Hz. Right: crystal structure of CDC25B (PDB: 2A2K24) highlighting
residues experiencing exchange in the relaxation dispersion experiments. Size of sphere indicates
relative magnitude of Rex calculated by relaxation dispersion curve modeling. The C-terminal helix
is denoted by the dashed ellipse.
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V422 that have relatively similar exchange rates, representing correlated local motion of these
groups in the milli-second timescale. Importantly, no motion on µs-ms time scale was observed
for any residues within 10 Å of the active site or within the C-terminal helix.
Previous molecular dynamics simulations indicated that the CDC25B C-terminal
residues (amino acids 531-550) are partially unfolded or disordered5,6. To the contrary, our
experimental studies of the backbone dynamics clearly demonstrate that these residues are well
ordered on ps-ns timescales, with an average S2 of greater than 0.9 for residues in this region.
Additionally, a lack of any correlated exchange in this region on longer time scales in the µs-ms
range indicates that this helix does not undergo any partial unfolding.
2.4 Validation of the CDC25B crystal structure in solution
In order to determine whether the crystal structure of CDC25B correctly reflects the protein
conformation in solution or whether the crystal structure is distorted by crystal packing, we
Figure2.5.Residual dipolar couplings indicate thatCDC25Bcrystal structure is representative
of its structure in solution. Correlation of predicted and experimental residual dipolar couplings.
Alignment tensor, Q-factor, and Euler angles are given. Closed circles represent the CDC25B
catalytic domain sequence from385 to 530, open circles represent theC-terminal helix from531
to 551. Left: correlations for positively charged gel sample (50+M). Right: correlations for
negatively charged gel sample (50-S).
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measured residual dipolar couplings (RDCs). RDC measurements provide information on the
orientation of bond vectors relative to amolecular frame of alignment, and thus have been shown
to provide reliable data for comparative analysis between a crystal structure and the structure in
solution22,23. Specifically, comparing calculated and experimental RDCvalues is a powerful tool
in validating the crystal structure22. In order to measure RDC values, the protein must be weakly
aligned with respect to the overall magnetic field to avoid rotational averaging of the RDCs. To
this endwe aligned the protein using both positively and negatively charged polyacrylamide gels
as described previously24.Wedetermined approximately 110 1DHNRDCsmeasurements for each
alignment (Figure2.5).Comparisonbetween theexperimentalRDCvaluesandvaluescalculated
for thepublishedCDC25BC473Scatalyticdomaincrystal structure (PDB:2A2K25) yields avery
good agreement, with correlation coefficients of 0.96 and 0.97 for the protein in positively and
negatively charged alignment media respectively (Figure 2.5). Importantly, RDCs for both the
C-terminal helix and the active site agree verywell with the RDCvalues predicted for the crystal
structure. For example, the correlation coefficients for the RDCs for residues in the C-terminal
400 420 440 460 480 500 540520
X-ray structure
TALOS+ (NMR)
Sequence
Figure 2.6. Results of TALOS+ secondary structure prediction from the chemical shifts of the
CDC25B C473S catalytic domain. The program TALOS+ was employed to predict secondary
structure elements from the experimentally determined chemical shifts of CDC25B. Results are
shown with the sequence, predicted structural element, and a confidence value as output by the
TALOS+ program.
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helix are 0.95 and0.91 inpositively andnegatively chargedgels, respectively.These results from
two independent alignments clearly indicate that the structure of CDC25B C473S in solution is
very close to the structure determined by X-ray crystallography. To additionally examine the
CDC25B C473S conformation in solution, we performed an analysis of the chemical shifts for
all assigned resonances using the TALOS+ program26, which predicts secondary structure
elements fromexperimentally determined chemical shift data. The resulting secondary elements
predicted from this analysis are in close agreement with those found in the crystal structure
(Figure 2.6).
2.5 Biophysical characterization of the CDC25B-CDK2/CycA interaction in vitro
Once the we had explored the conformational dynamics and structure of CDC25B in solution,
we turned to experiments characterizing the CDC25B-CDK2/Cyclin A interaction. We first
measured the heat of binding by isothermal titration calorimetry ITC, from which the Kd and
stoichiometry can be derived. Curve fitting of the heat of binding in our ITC experiments
produced a Kd of 1.9 µM (Figure 2.7). As expected from previous studies10, the stoichiometry of
the complex was determined to be 1-to-1. In addition to ITC, we measured the Kd for the
CDC25B-CDK2/Cyclin A interaction using biolayer interferometry. Global fitting analysis
determined the binding kinetics of the CDC25B-CDK2/Cyclin A interaction to be 1.28x104 ±
1.84x102 M-1s-1 and 1.58x10-2 ± 1.08x10-4 s-1 for kon and koff respectively. This yielded Kd of 1.2
± 0.02 µM which agrees well with our ITC experiments.
To map the CDC25B-CDK2/Cyclin A binding interface in vitro, we employed NMR to
analyze the CDC25B C473S backbone amide chemical shift perturbations in the presence of
CDK2/Cyclin A. Initial experiments used the CDC25B catalytic domain containing it’s
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unstructuredC-terminal tail,whichhasbeen shown tobeoneof the twokey sites for high-affinity
binding to CDK2/Cyclin A9. However, due to complex formation with CDK2/Cyclin A, the
spectrum for CDC25B was completely broadened and therefore was unusable for analysis. To
circumvent this, we expressed a truncated CDC25B (372-551) that included only the CDC25B
catalytic domain without the unstructured C-terminal tail. The reduction in affinity due to this
truncation resulted in an observable 1H15N-HSQCspectra forCDC25B, allowing for the analysis
of chemical shift perturbations due to CDK2/Cyclin A binding (Figure 2.8) This analysis
revealed that the binding interface on CDC25B extends across the entire face of the domain
between the enzymatic active site to the previously described protein-protein interaction
Figure 2.7. Biophysical determination of the CDC25B-CDK2/Cyclin A binding affinity. Left:
ITC binding analysis of the CDC25B-CDK2/Cyclin A interaction. Right: biolayer interferometry
association and dissociation curves. Colored curves correspond to CDC25B at various
concentrations: black, 50 μM; dark gray, 25 μM; light gray, 12.5 μM;maroon, 6.25 μM; red, 3.125
μM; orange, 1.56 μM; blue, 0.78 μM; aqua, 0.39 μM; light green, 0.2 μM; dark green, 0.1 μM. Plot
of Req versus CDC25B concentration is inlaid.
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“hotspot” residues7. (Figure 2.8). Despite the number of residues showing chemical shift
perturbations due to CDK2/Cyclin A binding, many of the shifts are small and still more
resonances remain unperturbed, and therefore it is highly unlikely that the CDC25B catalytic
domain undergoes any major structural rearrangement upon binding to CDK2/Cyclin A.
In order to determine the region of the unstructured CDC25B C-terminal tail (552-566)
involved in the interaction with CDK2/Cyclin A, we took advantage of carbon-detected NMR
experiments. Observation of unfolded and unstructured proteins by amide-detected NMR is
hindered by both a lack of resonance peak dispersion on the 1H15N-HSQC spectra as well as
unfavorable exchange rates of the amide proton with water, which results in loss of resonances
due to strong peak broadening. Previous studies have shown that carbon-detected NMR is a
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Figure 2.8. CDK2/Cyclin A contacts the catalytic domain of CDC25B. Left: chemical shift
perturbations on a CDC25B (372-551) 1H15N-HSQC in the presence (red) and absence (black) of
CDK2/Cyclin A. Right: global chemical shift perturbations mapped onto the CDC25B crystal
structure (PDB: 2A2K24). Residues with amide chemical shift perturbations greater than 3 standard
deviations are shown in red, greater than 2 standard deviations are shown in orange, greater than 1
standard deviation are in yellow. Unobserved or unassigned residues are shown in bronze, residues
with observed amides without significant chemical shift perturbations are shown in gray.
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valuable tool to overcome these problems27, owing to the fact that backbone carbons are not
affected by amide exchange and a show greater chemical shift dispersion for random coil
residues. For these reasons, we assigned backbone chemical shifts for the C-terminal tail of
CDC25B in the presence and absence of CDK2/Cyclin A. For samples where CDK2/Cyclin A
is present, a loss of several peaks was observed corresponding to the C-terminal residues 551 to
563 (Figure 2.9). This finding is in agreement with previous mutagenesis studies that found
residues R556 and R562 in particular have a detrimental effect on the rate of catalysis for
CDC25B toward phosphorylated CDK2/Cyclin A substrate9. These results demonstrate that
CDC25B interacts with CDK2/Cyclin A through both the well-folded catalytic domain as well
as the unstructured C-terminal tail (Figure 2.10).
Figure 2.9.Residues in theC-terminal
tail of CDC25B interact with CDK2/
Cyclin A. CACO carbon-detected
spectra for CDC25B containing the C-
terminal unstructured region (552 –
566) in the presence (red) and absence
(black) of CDK2/Cyclin A.
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Figure 2.10. The CDC25B-CDK2/Cyclin A
interaction is mediated through multiple
contacts. A model of the CDC25B-CDK2/
Cyclin A interaction showing the contacts
between both the CDC25B catalytic domain
and the C-terminal tail.
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2.6 Characterization of the CDK2/CycA-Mre11 interaction in vitro
In addition to its interaction with CDC25B, the CDK2/Cyclin A has been shown to directly
interact with the core DNA damage repair proteinMre1111. Previous reports have indicated that
the C-terminal 76 residues of Mre11 (hereafter called Mre11C76) are sufficient to maintain its
interaction with the CDK2/Cyclin A complex11. To characterize this interaction we used the
Mre11C76 protein fragment for NMR and ITC experiments. As predicted using bioinformatics
analysis of this sequence, the Mre11C76 is unstructured in solution as demonstrated by the lack
of resonancepeakdispersionon the 1H15N-HSQCspectrum.Toenable themappingof the regions
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Figure 2.11. Mre11C76 interacts directly with the CDK2/Cyclin A complex in vitro. Left: ITC
binding analysis of the CDK2/Cyclin A-Mre11C76 interaction. Right: A portion of the
Mre11C76 1H15N-HSQC spectrum in the presence (blue) or absence (red) of CDK2/Cyclin A.
Several residues showing loss of peak intensity are labeled.
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of Mre11C76 that interact with CDK2/Cyclin A, we assigned the backbone amide resonances for
this protein fragment. Of the observed 1H-15N resonance peaks, 98% were unambiguously
assigned to the corresponding amino acid, representing 83 % of the overall protein fragment
(Appendix Figure 2.A3). The unobserved 17 % of amides likely undergo exchange with water
on an unfavorable timescale for observation by NMR. For this reason, we measured backbone
resonances forMre11C76. Because amide exchange does not affect backbone carbon resonances,
the vast majority of these can be observed. Of all residues in the Mre11C76 protein fragment, we
observed 94% of the 13CO-13Cα resonance peaks, and 94% of the those were unambiguously
assigned to the corresponding amino acid (Appendix Figure 2.A4). The remaining 6 % of
residues were unable to be assigned due to peak overlap in certain parts of the spectrum.
To characterize the Mre11 – CDK2/Cyclin A interaction, we employed ITC and NMR.
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Figure 2.12. Carbon-detected NMR experiments show the Mre11C76-CDK2/Cyclin A
interaction. A portion of the Mre11C76 CACO spectrum in the presence (blue) or absence (red)
of CDK2/Cyclin A. Several residues showing loss of peak intensity are labeled.
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First we tested the affinity of the binding between Mre11C76 and the CDK/Cyclin A complex.
Quantification of the binding affinity by isothermal titration calorimetry produced aKd of 15 µM
for the complex (Figure 2.11). Interestingly, the stoichiometry of the interaction as determined
by ITC was 2:1 Mre11 to CDK2/Cyclin A. Mapping of the Mre11C76 residues that interact with
the CDK2/Cyclin A complex was performed by collecting NMR spectra for 13C 15N-labeled
Mre11C76 in the presence ofCDK2/CyclinA. Strong peak broadeningwas observed forMre11C76
residues involved in the interaction with CDK2/CyclinA due to the slower molecular tumbling
of the complex, while sharp resonance peaks were observed for the unrestricted regions of
Mre11C76 (Figure 2.11, Figure 2.12). A combined analysis of the 1H-15N and 13C-13Cα peak
broadening indicates that two distinct sequences are involved in the interaction with CDK2/
Cyclin A (Figure 2.13). Both motif 1 (aa 654-658) and motif 2 (aa 684-701) contain a
hydrophobic core preceded by a short acidic sequence. These results indicate that the Mre11 C-
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Figure 2.13. Mre11C76 interacts with the CDK2/Cyclin A complex through two motifs.
Combined analysis of peak intensity for each residue derived from 1H15N-HSQC and 13C-
detected experiments.
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terminus interacts directly with the CDK2/Cyclin A complex in vitro and is mediated by two
motifs in the Mre11 C-terminus.
To understand how these twomotifsmediate theMre11-CDK2/CyclinA interaction, we
introduced mutations into Mre11C76. Upon mutation of two residues in the hydrophobic core of
the firstmotif to alanines (F654A, P655A), the interaction of this entiremotifwithCDK2/Cyclin
A is abolished, however the second motif remains bound (Figure 2.14). Conversely, truncation
of the protein at residue 674 prior to the secondmotif does not affect the interaction between the
first motif and CDK2/Cyclin A (Figure 2.14). Mre11C76 contains an SQSQ motif (residues
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Figure 2.14.Bothmotifs onMre11C76 interact with CDK2/Cyclin A independently.Left: 1H15N-
HSQC spectrum of Mre11C76 F654A/P655A mutant in the presence (green at 1:1 molar
equivalent, blue at 1:2) and absence (red) of CDK2/Cyclin A. Several residues showing loss of
peak intensity are labeled. Right: 1H15N-HSQC spectrum for Mre11C76 truncated at residue 674
in the presence or absence of CDK2/Cyclin A. Colors are as described in A.
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674-677) between the two CDK2/Cyclin A binding motifs; such SQ and TQ repeats have been
shown previously to be potential phosphorylation sites for the DNA damage related kinases
ATM and ATR28, and therefore we wanted to probe the effect of phosphorylation at this site of
Mre11C76 onCDK2/CyclinAbinding in vitro.Mutation of the SQSQmotif to a phosphomemetic
EQEQ does not affect the interaction of either motif (Appendix Figure 2.A4), indicating that
phosphorylation at this site is unlikely to regulate the direct binding between Mre11C76 and
CDK2/Cyclin A.
To identify potential binding sites for Mre11C76 on CDK2/Cyclin A we made the Cyclin
A I213Emutant. This mutation affects a key residue in the so-called RxL binding site on Cyclin
A, which has been shown previously to interact with a wide variety of peptides29. The 1H15N-
HSQC spectra of the Mre11C76 peptide in the presence of CDK2/Cyclin A I213E mutant shows
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significantly less broadening formanyof the residues involved in both bindingmotifs, indicative
of a weaker binding affinity for the mutant complex (Figure 2.14).
2.7 Discussion
In this study,we characterized theCDC25Bcatalytic domain in solution, determined the binding
interfaces onCDC25Bresponsible for its interactionwithCDK2/CyclinA, andcharacterized the
novel CDK2/Cyclin A interaction with Mre11. We found that the catalytic domain of CDC25B
is relatively rigid in solution, and that the structure in solution is very close to the crystal structure.
This finding is in contrast to previous molecular dynamics studies of this protein; specifically,
that the 20 amino acids in the α-helix near the C-terminus in the crystal structure predicted to be
dynamic in solution by molecular dynamics did not show any dynamics experimentally5,6.
Experimental analysis of backbone dynamics on slow timescales shows no conformational
exchange in either the C-terminal helix or anywhere near the active site, and therefore is highly
unlikely to undergo any partial unfolding as previously suggested. Because we observed no
backbonedynamicsnear theactive site, it is unlikely that there are any transient or crypticbinding
pockets near this site.
Our work has important implications for future structure-based small molecule design,
since it provides strong evidence that the crystal structure of the CDC25B catalytic domain
accurately reflects its conformation in solution. This study further demonstrates a need to
experimentally validate findings from molecular dynamics simulations, particularly in cases
where this may directly impact design of small molecule inhibitors.
Additionally, we have determined binding affinity of the CDC25B-CDK2/Cyclin A
interaction by several methods, and characterized aspects of the protein-protein interaction by
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NMR. Though a computational model of this interaction has been previously generated25, these
results are the first to directly observe the binding interface on the CDC25B catalytic domain or
on its C-terminal tail. Our results show that the CDC25B catalytic domain does not undergo any
major structural rearrangements upon binding to CDK2/Cyclin A, and that the residues after the
C-terminal α-helix of the catalytic domain are unstructured and several of these residues contact
the CDK2/Cyclin A complex.
Our characterization of the novel Mre11-CDK2/Cyclin A protein-protein interaction
revealed that the interaction is mediated through twomotifs on theMre11 C-terminus. Previous
experiments demonstrated that loss of even the final 13 residues of the Mre11 C-terminus
significantlyweakened its ability to bindCDK2/CyclinA11. Our experiments provide a rationale
for this observation; the majority of the second CDK2/Cyclin A binding motif is lost upon
removal of theseC-terminal residues, though the first bindingmotif remains and thereforeMre11
retains some binding affinity.
Correspondingly,wehavedemonstrated throughmutagenesis that theMre11C-terminus
interacts at least in part with the RxL-binding pocket on Cyclin A. Interestingly, mutation in the
RxL-binding pocket disrupts the binding of bothMre11motifs. Such a result indicates that both
Mre11motifsmay interactwith the same site onCyclinA.The similar character of the sequences
of the two motifs further helps rationalize this hypothesis; both contain several negatively
charged aspartic or glutamic acid residues, followed by a pair of hydrophobic residues.
The Mre11-CDK2/Cyclin A interaction is not the first observation of a peptide-CDK2/
Cyclin A interaction occurring through twomotifs. Both CDK2/Cyclin A substrates and protein
inhibitors have been shown to interact with the CDK2/Cyclin A complex through two critical
motifs. For example, the CDK2/Cyclin A substrates p107, E2F1, and Rb all interact with both
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the CDK2 active site as well as the RxL-binding site30. In addition to CDK2/CyclinA substrates,
inhibitors of this complex also bind through multiple motifs. An example is the CDK2 protein
inhibitor p27Kip1, which interacts with the CDK2/Cyclin A complex through both the RxL-
binding site as well as a second regulatory site on the CDK2 N-terminal lobe31,32. Interestingly,
approximately 40 residues separate these two binding sites, which is similar to the distance
between the two interaction motifs in Mre11. These studies indicate that there are multiple sites
on the CDK2/Cyclin A complex with a capacity for peptide binding. Our mutagenesis studies
regarding the Mre11-CDK2/Cyclin A interaction indicate that Mre11 interacts at least in part
with the Cyclin A RxL-binding pocket. However, given the number of peptide binding sites on
CDK2/CyclinA it is possible that the one of the twomotifs onMre11 interacts with a second site
on CDK2/Cyclin A, but disruption of just the RxL-binding site is sufficient to disrupt the entire
interaction.
2.8 Experimental Procedures
Expression and purification of the CDC25B catalytic domain
The CDC25B catalytic domain (372-551) and variants were expressed in E. coli BL21 (DE3)
with an N-terminal GST tag. The CDC25B cDNA with an N-terminal TEV cleavage site was
purchased fromGenscript and cloned into a pGST-21a vectorwithNcoI/XhoI.Cellswere grown
to in either LB or labeledM9medium. After 16 hr induction with 0.5 mM IPTG at 18 °C, E. coil
cells were lysed by cell disruption in a buffer containing 50 mM Tris (pH 8.0), 150 mM NaCl,
1mMTCEP, and 0.5mMPMSF. The cell lysatewas subjected to centrifugation, after which the
soluble fraction was incubated with glutathione resin. The resin was then washed with lysis
buffer, and eluted with lysis buffer containing 50 mM L-glutathione. The eluate was
50
proteolytically cleaved with TEV protease, followed by S-75 size exclusion chromatography in
buffer containing 50 mM Tris (pH 8.0), 50 mM NaCl, and 1 mM TCEP. Pure fractions were
pooled and frozen at -80 °C.
Expression and purification of CDK2/Cyclin A proteins
The CDK2/Cyclin A complex was expressed in E. coli BL21 (DE3) by co-expression of TEV
cleavable N-terminally His tagged full-length human CDK2 in a pET24 vector, and residues
173-432 of human Cyclin A with an N-terminal His-Smt3 tag in a pET24 vector (generously
gifted by Dr. Matthew Young, University of Michigan). The E. coil cells were lysed in a buffer
containing 50 mM Tris (pH 8.0), 500 mMNaCl, 1 mM β-mercaptoethanol, and 0.5 mM PMSF
after a 16 hr induction with 0.1 mM IPTG at 18 °C. After centrifugation, the soluble cell lysate
was purified usingNi-affinity chromatography. The fractions containing 1:1molar ratio CDK2/
Cyclin A complex were pooled and proteolytically cleaved with both TEV andULP1 proteases,
followed by S-75 gel filtration chromatography in buffer containing 50 mM Tris (pH 8.0), 150
mM NaCl, and 1 mM TCEP. Pure fractions were pooled and frozen at –80 °C.
Expression and purification of Mre11 proteins
Mre11C76 and variants were expressed in E. coli BL21 (DE3) as 3C protease-cleavable N-
terminallyHis taggedpeptides cloned into thepET32vector.Cultureswere inducedwith0.1mM
IPTG at 18 °C overnight, and then lysed in a buffer containing 50 mM Tris (pH 7.5), 150 mM
NaCl, 1 mM (TCEP), and 0.5 mM PMSF. The soluble cell lysate was purified using Ni-affinity
chromatography. The eluted fractions were pooled and proteolytically cleaved with the
rhinovirus 3C protease, followed by a second Ni-affinity chromatography step to separate the
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cleaved protein from the tag. Pure fractionswere pooled and frozen at –80 °C in buffer of 50mM
sodium phosphate (pH 6.5), 50 mM NaCl, and 1 mM TCEP.
NMR spectroscopy and assignment of CDC25B catalytic domain
Samples for backbone assignment were made with 13C15N-labeled CDC25B C473S (residues
372-551) prepared in a buffer containing 50 mM Tris (at either pH 7.0 or 8.0), 50 mM NaCl, 1
mM TCEP and 5 % D2O. Spectra were acquired at 30 °C on a 600MHz Bruker Avance III
spectrometer equiped with cryoprobe, running Topspin version 2.1. Backbone assignment was
done using a series of triple-resonance experiments including HNCACB, CBCA(CO)NH,
HNCA, HN(CO)CA, HNCO, HN(CA)CO, and 15N-separated NOESY-HSQC33–35. Processing
and spectral visualization was performed using NMRPipe36 and Sparky37.
NMR spectroscopy for CDC25B-CDK2/Cyclin A
For 1H15N-HSQCexperiments, uniformly 15N labeledCDC25B (residues 372-551) at 40µMwas
mixed with unlabeled CDK2/Cyclin A complex at 80 µM in a buffer of 50mM Tris (pH 8.0)
50mM NaCl, 1mM TCEP and 5% D2O at 25 °C. For 13C-detected experiments, spectra for
samples containing 100 µM uniformly 13C15N labeled CDC25B (residues 372-566) and 100 µM
unlabeled CDK2/Cyclin A were acquired in a buffer of 50mM Tris (pH 8.0) with 50mMNaCl,
1mM TCEP and 5% D2O at 30 °C. All spectra were acquired on a 600MHz Bruker Avance III
spectrometer running Topspin version 2.1 and equippedwith a TCI cryogenic probe. Processing
and spectral visualization was performed using NMRPipe36 and Sparky37.
NMR-based relaxation measurements
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All relaxation measurements were acquired at 30 °C using 15N-labeled CDC25B C473S or the
wild type CDC25B in buffer containing 50 mM Tris (pH 7.0), 50 mM NaCl, 1 mM TCEP, and
5 % D2O. T1 and T2 relaxation measurements, as well as the 1H-15N heteronuclear NOE
measurement were obtained using experiments similar to those described by Bax et al.19. The
relaxation delays for the T1 and T2 experiments were 10, 30, 70, 150, 330, 750, 1500, 2200ms,
and 17, 34, 51, 68, 85, 102, 136, 170ms, respectively. 1H-15N heteronuclear NOE experiments
were recorded as interleaved experiments with and without NOE saturation. Experimental
relaxation delays were set at 6 seconds for T2and 1H-15N heteronuclear NOEmeasurements, and
4 seconds for T1 measurements. T2 and 1H-15N heteronuclear NOE experiments were performed
in duplicate. T1 and T2 values were calculated by fitting relaxation curves in Sparky37.
Relaxation dispersion experiments were recorded at 30 °C at 600MHz using a series of
CPMG pulse trains as reported previously21. Two-dimensional spectra were acquired with
CPMG field strengths of 25, 50, 75, 150, 300, 750, and 1000 Hz. Peak lists with intensities were
used as input into the program NESSY for calculation of R2,eff and subsequent model fitting17.
Model-free analysis
Model free analysiswasperformedusing themodelfree4 andFASTModelfreeprograms39,40. The
PDB structure used was prepared using the pdbinertia program41, and the initial estimate for the
diffusion tensor (Dpar/per) was obtained using the r2r1_diffusion program42. An axially symmetric
diffusion model was used with the following initial parameters: rotational correlation time τc =
11.4 µs, diffusion tensor Dpar/per = 1.25, and rotation angles θ = 6.3 °,Φ = -220 °, which describe
the re-orientation of the molecule to the principal axis system. The protocol for model selection
was asdescribedbyMandel et al43. FASTModelfreewas employed to iteratively adjust theglobal
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parameters between optimizations of the internal parameters (S2, τc, etc.). The global parameters
converged after 8 iterations.
Measurement of residual dipolar couplings
Samples for measurement of residual dipolar couplings were made using 15N CDC25B C473S
in buffer containing 50mMTris (pH7.0), 50mMNaCl, 1mMTCEP,with 5%D2Oand acquired
at 30 °C. Charged polyacrylamide gels for alignment were prepared as described previously24.
Samples were prepared for isotropic measurements (gel-free) and two different anisotropic
measurements, including a positively charged gel (50+M) and a negatively charged gel (50-S).
1JNH couplings were measured for isotropic and anisotropic using the IPAP experiment44.
Residual dipolar couplings were calculated by subtracting the 1JNH couplings of the isotropic
sample from thecouplings for the anisotropic sample.Comparisonof experimental andpredicted
RDCvalueswas performedwith theDCprogram inNMRPipe36, using PDBcode 2A2K25 for the
RDC back calculations.
Isothermal titration calorimetry
CDC25B C473S (residues 372-566) and CDK2/Cyclin A were extensively dialyzed at
4 °C against a buffer containing 50mM sodium phosphate (pH 7.0), 50mM NaCl, 1mM TCEP
and degassed prior to the experiment. Experiments were performed using the VP-ITC system
(MicroCal). CDC25BC473S at 100 µMwas injected in 10 µL volumes into the calorimetric cell
containing 10 µM CDK2/Cyclin A at 25 °C. Data was analyzed with Origin 7.0 (OriginLab).
Experiments for Mre11C76 and CDK2/Cyclin A were performed as above with an
alternate buffer of 50mM sodium phosphate (pH 6.5), 50mM NaCl, 1mM TCEP, and
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concentrations of 200 µM Mre11C76 in the injectant and 10 µM CDK2/Cyclin A in the
calorimetric cell at 25 °C.
Biolayer interferometry for the CDC25B-CDK2/Cyclin A interaction
CDK2/CyclinAprotein as previously describedwith the addition of aN-terminalAvi-tagged on
CDK2was co-purifiedwith the biotin ligase BirA to produce biotinylatedCDK2/CyclinA. This
protein was immobilized on a Super streptavidin sensor (ForteBio, Menlo Park, CA, USA) in a
PBS buffer during a 600 second incubation at 25 °C. CDK2/Cyclin A immobilized sensors were
then placed in a cell containingCDC25BC473S (residues 372-566) at various concentrations for
300seconds, followedbya300secondwashoutwithPBS.Datawascollectedandanalyzedusing
the Octet RED96 system and software.
NMR spectroscopy of the Mre11 C-terminal domain
NMR experiments for assignment were acquired for uniformly 13C15N labeled Mre11C76 at 140
µM in a buffer of 50mM Tris (pH 7.5) 50mMNaCl, 1mM TCEP and 5% D2O at 25 °C. Spectra
were acquired on a 600MHz Bruker Avance III spectrometer running Topspin version 2.1 and
equipped with a TCI cryogenic probe. Backbone assignment was doneusing a series of triple-
resonance experiments includingHNCACB,CBCA(CO)NH,HNCA,HN(CO)CA,HNCO, and
HN(CA)CO, as well as several 13C-detected experiments including CACO, CBCACO, and
CANCO. Samples for characterization of the Mre11C76-CDK2/Cyclin A protein-protein
interaction were acquired in a buffer of either 50mM Tris (pH 6.5) or 50mM phosphate buffer
(pH 6.5), with 50mMNaCl, 1mM TCEP and 5% D2O at 30 °C. The same conditions were used
for all experiments with Mre11 mutant proteins. Processing and spectral visualization was
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performed using NMRPipe36 and Sparky37.
Notes
Characterization of the CDC25B catalytic dynamics in solution has been published45 by George
Lund andTomaszCierpicki as "SolutionNMRstudies reveal no global flexibility in the catalytic
domain of CDC25B" (2014) Proteins 82, 2889–95.
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Appendix Figure 2.A1. Comparison of chemical shifts between CDC25B WT and the C473S
mutant. A) Overlap of 1H15N-HSQC spectra for CDC25B WT (black) and C473S (red). B)
Comparison of 1H chemical shifts for the same residues in CDC25B WT and C473S mutant
proteins from the 1H15N-HSQC spectra. C) Same as in B, comparing 15N chemical shifts.
Analyses B and C omit 6 residues from the mutant protein including and immediately adjacent
to the mutated residue (residues H472, S473, S476, S477, E478, and R479) that differed
significantly enough in chemical shift such that they could not be definitely assigned in theWT
spectrum.
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AppendixFigure 2.A2.Comparison of relaxationmeasurements betweenCDC25BWTand the
C473S mutant. A) R1 values for CDC25B WT (black dots, solid line) and the C473S mutant
(white dots, dotted line). A schematic of CDC25B secondary structure is shown above. B) Same
as in A, comparing R2 values.
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HSQC spectrum. Left: entire 1H15N-HSQC spectrum
is shownwith assignment; right: zoomed in section of
the 1H15N-HSQC spectrum denoted by the dotted box
on the left side.
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Chapter 3
Identification of inhibitors of the CDC25B-CDK2/Cyclin A interaction through
fragment screening by NMR
3.1 Abstract
CDC25 phosphatases are key cell cycle regulators and represent very attractive but challenging
targets for anti-cancer drug discovery. Here, we explored whether fragment-based screening
represents a valid approach to identify inhibitors of CDC25B. This resulted in identification of
2-fluoro-4-hydroxybenzonitrile, which directly binds to the catalytic domain of CDC25B.
Interestingly, NMR data and the crystal structure demonstrate that this compound binds to the
pocket distant from the active site and adjacent to the protein-protein interaction interface with
CDK2/Cyclin A substrate. Furthermore, we developed a more potent analog that disrupts
CDC25B interaction with CDK2/Cyclin A and inhibits dephosphorylation of CDK2. Based on
these studies, we provide a proof of concept that targeting CDC25 phosphatases by inhibiting
their protein-protein interactions with CDK2/Cyclin A substrate represents a novel, viable
opportunity to target this important class of enzymes.
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3.2 Introduction
As described in Chapter 1, the CDC25 family of dual-specificity protein phosphatases plays a
central role in cell cycle regulation by activating the cyclin-dependent kinases (CDKs) through
the removal of inhibitory phosphorylations.1 CDC25 family member CDC25B regulates the G2/
M phase transition by removing two inhibitory phosphate groups from the ATP binding loop of
the CDK2 kinase.2,3 CDC25B is often overexpressed in various cancers, leading to excessive
CDK2/Cyclin A activation and aberrant cell cycle progression resulting in poor clinical
outcomes.4–7 Genetic studies have shown the vital role of CDC25B in cancer for tumor cells
growth, supporting that CDC25B is an attractive therapeutic target for inhibition by small
molecules.8–10 Indeed, the CDC25 phosphatases have been actively pursued as cancer drug
targets for over twenty years.11,12 To date, all efforts to inhibit CDC25phosphataseswere focused
on targeting the catalytic sites of these enzymes,11,13 which are unusually small and shallow
withoutwell-defined binding pockets,makingCDC25s somewhat recalcitrant to drug discovery
efforts.14 Furthermore, the presence of a highly reactive catalytic cysteine in the active sites of
CDC25s hampers screening and drug design efforts due to covalent binding and irreversible
inhibition by diverse classes of small molecules.11 Indeed, majority of well-studied and themost
potent inhibitors of CDC25s discovered to date, including quinone and Vitamin K3 derivatives,
are known to covalently modify cysteines in CDC25s,11,15 raising questions about their potential
toxicity and limiting their therapeutic applications.16 Furthermore, no biophysical or structural
characterization of known CDC25 inhibitors has been reported to date, leaving the mechanism
of their binding largely unknown.
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3.3 NMR-based fragment screening identifies a ligand of CDC25B
To assess whether small molecule compounds binding to CDC25B can be identified, we
employed fragment-based screening approach.An in-house library of fragment-like compounds
consisting of approximately 1500 chemically diverse small molecules was screened by NMR
spectroscopy through theobservationof 1Hand 15Nchemical shift perturbationson 1H-15NHSQC
NMR spectra for uniformly 15N labeled CDC25B catalytic domain. Through this screen, we
found 2-fluoro-4-hydroxybenzonitrile, (compound 1), as the only compound that binds to
CDC25B (Figure 3.1). To map the binding site of 1 on CDC25B we analyzed chemical shift
perturbations using previously determined backbone assignment17. Interestingly, we found that
1 does not bind to the active site but rather perturbs a set of residues in a distal site on CDC25B.
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Figure 3.1. Identification of compound 1 as a novel CDC25B ligand by fragment-based
screening. Left: a portion of the 1H-15N HSQC spectrum for the CDC25B catalytic domain in
the presence (red) and absence (black) of 2mM 1. Right: chemical structure of compound 1.
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3.4 Compound 1 binds a pocket on CDC25B adjacent to critical residues for the CDC25B-
CDK2/Cyclin A protein-protein interaction
To accurately establish the binding mode of this compound we determined a high-resolution
crystal structure of 1 bound to the CDC25B (Figure 3.2). The structure revealed that 1 binds to
a relatively small but well-defined pocket on CDC25B located approximately 15Å away from
theactive site inagreementwith thechemical shift perturbations.Thisbindingpocket isprimarily
comprised of the Phe386, Leu398, Cys484, Arg488, andMet505 side chains. The phenyl ring of
1 inserts between the side chains of Leu398 and Arg488, forming a hydrophobic and cation-π
interactions, respectively (Figure3.2).The fluorineof1 is present in twoconformations,withone
conformer pointing towards the backbone of Cys484 and the second pointing towards the
solvent. The nitrile is partly solvent exposed, and the nitrile nitrogen replaces a well-defined
R488
R492
15 Å
4.3 Å
R485 D397
L398 K399
F386
R488
R492
C484
M505
G380
Figure 3.2. Co-crystal structure of CDC25B bound to compound 1. Left: crystal structure of 1
bound to CDC25B. Dark gray surface denotes the enzymatic active site. Two arginine residues
involved in interactionwithCDK2/CyclinA substrate are labeled and shown in red. The distance
between the catalytic cysteine and1 is shown.Right:Molecular details of the interactionof1with
CDC25B binding pocket. Distance between position 6 of 1 and the sulfate ion is given (PDB ID:
4WH7). The hydrogen bond network between the hydroxyl of 1 and four waters in the binding
pocket is also shown.
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water molecule found in the apo-structure near the backbone of Arg485. Interesting feature of
this binding site is the presence of numerouswell orderedwatermoleculeswhich forma network
of hydrogen bonds. These waters are hydrogen bonded to backbone carbonyl and amide of
Met505 and amides of Lys399 and Gly380 (Figure 3.2). Binding of 1 replaces water molecule
present in the structure of CDC25B and the hydroxyl group of 1 participates in a network of
hydrogen bonds with remaining waters (Figure 3.2).
Interestingly, several residues directly adjacent to the binding site of 1 were shown
previously to be involved in the protein-protein interaction between CDC25B and its substrate
CDK2.3,18 Basedonmutagenesis studies,Arg488 andArg492 inCDC25B (Figure 3.2) havebeen
shown to be required for CDK2 substrate recruitment through ionic interactions with Asp206.18
To further validate the importance of this site for interactionswithCDK2/CyclinA substrate, we
introduced the R492L mutation. We assessed the ability of the R492L mutant and wild-type
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Figure 3.3.Mutation in the compound 1 binding site disrupts the interaction between CDC25B
andCDK2/Cyclin A. AlphaLISA signal due to the protein-protein interaction betweenCDC25B
and the CDK2/Cyclin A complex. CDC25B WT is shown in black and the hotspot mutation
R492L is shown in red.
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CDC25B to interact with the substrate using an AlphaLISA-based protein-protein interaction
assay. Consistent with the previous report,18 we found that CDC25B R492Lmutant is unable to
interactwithCDK2/CyclinAsubstrate (Figure3.3).This result strongly supports our finding that
compound 1 binds to a functionally important site on CDC25B that is involved in the protein-
protein interactions with the substrate.
3.5 Structure guided design of higher affinity analogs of Compound 1
NMR experiments indicated that 1 binds to CDC25B with a relatively low affinity, which is
typical for fragment-like compounds.19 We subsequently explored which functional groups in 1
are essential for interactions with CDC25B. We found that removing either hydroxyl or nitrile
groups was detrimental for binding to CDC25B (not shown). Then we tested several
commercially available analogs of 1, and to rank their binding to CDC25Bwemeasured the sum
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Figure 3.4. Structure activity relationship (SAR) for 2-fluoro-4-hydroxybenzonitrile analogs.
Structures of compounds tested for binding to CDC25B. Sum Δ was calculated as a sum of the
chemical shift perturbations for eight of the most significantly perturbed amide resonances (in
Hz) at 2mM compound concentration.
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of chemical shift changes for eight of the most perturbed amide resonances. Elimination of the
fluorine at position R1 (compound 2) significantly decreased binding, while exchanging it for
chlorine (3) had no effect (Figure 3.4). Addition of a second fluorine, either at position R2 (5) or
R3 (6) enhanced binding, with a preference for the R2 position.
We then explored the possibility to improve 1 by linking to an adjacent sulfate ion that
was found in the CDC25B-1 crystal structure and interacts with the side chains of Arg488 and
Arg492 (Figure 3.2). Based on the structural data we designed and synthesized two compounds,
with a thio-ether at R3 position and either two- or three-carbon linker to the sulfate moiety
(Appendix Figure 3.A1). Compound 8 containing a three-carbon linker showed limited
improvement over 1, while 7 with a two-carbon linker showed more pronounced binding as
judged by more extensive chemical shift perturbations (Figure 3.4). Subsequently, we
determined the crystal structure of 7 in complex with CDC25B and found that indeed additional
3.0 Å
2.9 Å
2.8 Å
R485
D397
L398
K399
F386R488
R492
Figure 3.5. Co-crystal structure of CDC25B bound to compound 7.Molecular details of the
interaction of compound 7 with CDC25B (PDB ID: 4WH9). Distances between the sulfate
oxygens and the side-chain nitrogens of Arg488 and Arg492 are given.
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interactions are formedbetween the sulfate group of7 andArg488 andArg492,which contribute
to the enhanced binding of this compound (Figure 3.5). This finding further demonstrates the
feasibility of developing more potent analogs of 1.
3.6 Compound 7 inhibits CDC25B by disrupting theCDC25B-CDK2/Cyclin A interaction
We have selected compound 7, as the most potent and bulky compound, to assess the ability of
a small molecule to inhibit the interaction of CDC25B with the CDK2/Cyclin A substrate. For
this purpose we employed the AlphaLISA-based protein-protein interaction assay. A dose-
dependent decrease in the AlphaLISA signal was observed upon titration with 7, demonstrating
disruption of the CDC25B-CDK2/Cyclin A protein-protein interaction with the IC50 value
around 1 mM (Figure 3.6). Contrary, much weaker activity has been observed for compound 1,
which binds CDC25B with lower affinity. In addition, only 7 forms hydrogen bonds with two
-4.0 -3.5 -3.0 -2.5
100
IC50  7 = 1mM
pCDK2/CycA
CDC25B WT
1 (mM)
+
—
—
+
+
—
+
+
4
+
+
2
+
+
1
+
+
0.5
pCDK2
Log[compound] (M)
P
er
ce
nt
 In
hi
bi
tio
n Compound 1
Compound 7
7 (mM) — — 4 2 1 0.5
pCDK2IC50 1 > 5mM
-4.2 -4.0 -3.8 -3.6 -3.4 -3.2 -3.0 -2.8 -2.6 -2.4 -2.2
20
40
60
80
100
Y
 A
xi
s 
Ti
tle
X Axis Title -2.0
80
60
40
20
Figure 3.6. Small molecule ligand binding to the protein-protein interaction site inhibits
CDC25B activity. Left: activity of compound 1 and 7 in an AlphaLISA-based protein-protein
interaction assay. Right: In vitro phosphatase assay utilizing phosphorylated CDK2/Cyclin A as
a substrate for CDC25B in the presence or absence of 1 or 7. Remaining phosphorylated CDK2/
Cyclin A is shown as detected by western blot.
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arginines (Arg488 and Arg492) which are required for binding of CDK2/CyclinA substrate20
which may result in higher activity of this compound when compared to 1. Though activity of
7 is relativelymodest, this result provides a proof of principle that ligands that bind to this newly
identified site on CDC25B can prevent CDC25B from interacting with the substrate.
Finally, to determine whether disruption of the CDC25B-CDK2/Cyclin A protein-
protein interaction by a smallmolecule results in inhibition of CDC25B activity, we assessed the
effect of 7 in an in vitro phosphatase assay. We found that incubation with 7 results in a dose-
dependent inhibition of CDC25B phosphatase activity towards p-CDK2/Cyclin A substrate
(Figure 3.6). At the highest concentration of 7, CDC25B activity is completely inhibited and it
continues to show inhibitory effect down to 500 µM,with an apparent IC50 between 1 and 2mM.
Importantly, no inhibitory effect of1has been observed emphasizing that activity in phosphatase
1H (ppm)
1
5
N
 (
p
p
m
)
116
7.8
118
120
122
124
7.6 7.4 7.2
1H (ppm)
1
5
N
 (
p
p
m
)
116
7.8
118
120
122
124
7.6 7.4 7.2
Figure 3.7. Compound 1 and 7 interact with CDC25A. Left: A portion of the 1H15-HSQC of
CDC25A showing the largest chemical shift perturbations induced by compound 1. Right: 1H15N
chemical shift perturbations induced by compound 7. The same portion of the spectrum shown
for compound 1 is shown. In both spectra CDC25A without compound is shown in black.
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assay is correlatedwith binding affinity to CDC25B (Figure 3.6). These results strongly validate
that a small molecule that binds to the protein-protein interaction pocket distal from the active
site disrupts the interaction of CDC25BphosphatasewithCDK2/CyclinA substrate and inhibits
its phosphatase activity.
3.7 Compounds 1 and 7 also inhibit CDC25A
We have also assessed whether compounds 1 and 7 bind to CDC25A, a close homolog
of CDC25B.We found that 1 and 7 binds to CDC25A, although the chemical shift perturbations
are less pronounced than for CDC25B (Figure 3.7). In addition compound 7 inhibits the
interaction of CDC25A with CDK2/CyclinA with IC50=2.2 mM (Figure 3.8). The binding
pockets in CDC25A and CDC25B are very similar though it is likely that selectivity can be
achieved for more elaborated analogs.
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Figure 3.8. Inhibition of protein-protein interactions by compound 1 and 7. Left: effect of
titration with compound 1 on the interactions of CDC25A and CDC25B with CDK2/CycA.
Right: same plot as in A for compound 7.
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3.8 Discussion
In this study, through a fragment-based screening approach, we have identified a smallmolecule
binding site on CDC25B that is distant from the active site and is located adjacent to the residues
mediating substrate recognition. Although it has been previously speculated that this pocket
might represent a suitable site for inhibitor development,14 our study demonstrates for the first
time that: i) it is possible to identify small molecules that can bind to this site; ii) 2-fluoro-4-
hydroxybenzonitrile (compound 1) represents an attractive smallmolecule scaffoldwhich binds
to this site and can be further optimized intomore potent ligands; iii) compounds that bind to this
site can disrupt the protein-protein interaction of CDC25B with CDK2/Cyclin A substrate and
inhibit the phosphatase activity of CDC25B.
Despite extensive efforts to develop inhibitors ofCDC25phosphatases through targeting
the active site,11–13 no structural information for the phosphatase catalytic domain with bound
inhibitor has been reported to date. Here, we describe the structure of CDC25B catalytic domain
with two small molecule ligands that bind to a pocket in the vicinity of a protein-protein
interaction hot-spot. Interestingly, this pocket is relatively polar and fits a network of hydrogen
bonded water molecules. Ligands identified in our study can be likely improved through further
modifications to replace these water molecules and optimize contacts with the protein. For
example, the extensive network of intermolecular hydrogen bonds between biotin and
streptavidin is known to contribute to a very high affinity interaction.20 In summary, we propose
a novel approach to block activity of CDC25 phosphatases via inhibiting their protein-protein
interactions with the substrate as an attractive strategy to develop inhibitors for this important
class of enzymes.
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3.9 Experimental Procedures
Expression and purification of recombinant proteins
The CDC25B catalytic domain (372-551) and variants were expressed in E. coli BL21 (DE3)
with an N-terminal GST tag. The CDC25B cDNA with an N-terminal TEV cleavage site was
purchased fromGenscript and cloned into a pGST-21a vectorwithNcoI/XhoI.Cellswere grown
to in either LB or labeledM9medium. After 16 hr induction with 0.5 mM IPTG at 18 °C, E. coil
cells were lysed in a buffer containing 50 mM Tris (pH 8.0), 150 mM NaCl, 1 mM TCEP, and
0.5 mM PMSF. The soluble fraction of the cell lysate was purified using glutathione resin and
elutedwith lysis buffer containing 50mML-glutathione. The eluate was proteolytically cleaved
withTEVprotease, followedbyS-75 size exclusionchromatography inbuffer containing50mM
Tris (pH 8.0), 50 mMNaCl, and 1 mMTCEP. Pure fractions were pooled and frozen at –80 °C.
Thewild typeCDC25Acatalytic domain (331-524) andN-terminallyFlag taggedCDC25Awith
the C431S active site mutation were expressed and purified as described above.
pCDK2/Cyclin A was expressed in E. coli BL21 (DE3) by co-expression of three
proteins: full-length human CDK2 with a TEV cleavable N-terminal His tag in a pET24 vector,
residues 173-432 of human Cyclin A with an N-terminal His-Smt3 tag in a pET24 vector
(generously gifted by Dr. Matthew Young, University of Michigan), and full length xenopus
Myt1 kinase in the pGS21a vector (gifted fromDr. Sally Kornbluth, Duke University School of
Medicine).UnphosphorylatedCDK2/CyclinAwas expressed as above, butwithout the addition
of Myt1. After 16 hr induction with 0.1 mM IPTG at 18 °C, E. coil cells were lysed in a buffer
containing 50 mMTris (pH 8.0), 500 mMNaCl, 1 mM β-mercaptoethanol, and 0.5 mM PMSF.
The soluble cell lysatewas purified usingNi-affinity chromatography. The eluted fractionswere
pooled and proteolytically cleaved with TEV and ULP1 proteases, followed by S-75 size
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exclusion chromatography in buffer containing 50 mMTris (pH 8.0), 150 mMNaCl, and 1 mM
TCEP. Pure fractions were pooled and frozen at –80 °C.
NMR-based fragment screen
The fragment library used for screeningwas a combination of commercially available fragments
and compounds synthesized in-house. Samples for fragment screening were made with 80 µM
15N-labeledCDC25BC473S prepared in a buffer containing 50mMTris (pH 7.0), 50mMNaCl,
1 mM TCEP and 5 % D2O. Fragments were screened in mixtures of 20 compounds per sample
at 250 µM final concentration, in 5% DMSO. 1H-15N HQSC spectra were acquired at 30 °C on
a 600MHz Bruker Avance III spectrometer equipped with cryoprobe, running Topspin version
2.1. Processing and spectral visualizationwas performed usingNMRPipe21 and Sparky22. 1H-15N
HQSC peak assignments were determined previously17.
Crystallization and structure determination
Crystals of apo-CDC25B C473S ΔC (372-551) were produced as previously published3. For
compound 1, crystalswere transferred to themother liquor solution to containing 50mM 1 in 5%
DMSO to soak for 30minutes andwere then transferred to themother liquor solution containing
50 mM 1, 5% DMSO, and 20% glycerol for cryoprotection prior to freezing in liquid nitrogen.
For compound 7, crystals were transferred directly to the same cryoprotection solution in the
presence of 2mM 7 and 5%DMSO for 2minutes prior to freezing.Diffraction datawas collected
for the CDC25B-1 crystals using an X-ray difractometer at the Center for Structural Biology at
theUniversity ofMichigan.Diffraction data for theCDC25B-7 complexwas collected at the 21-
ID-F beamline at the Life Sciences Collaborative Access Team at the Advanced Photon Source.
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Thedatawas integratedandscaledusingHKL-300023 for1andMosflm24 for7andboth structures
were solved by molecular replacement with MOLREP25 using the known apo-CDC25B C473S
structure for the search model (PDB code: 2A2K)3. Refinement for both structures was
performed using REFMAC26, COOT27, and the CCP4 program suite28 (Appendix Table 3.A1).
Refinement of anisotropic B-factors was done in the late stages of refinement. The structure was
validated using the MOLPROBITY29 server.
Protein-protein interaction assay
C-terminally 6xHis tagged CDK2/Cyclin A complex and N-terminally Flag tagged CDC25B
C473S (372-566) were expressed and purified as stated above. Proteins were incubated together
at a final concentration of 10 nM each for 1 hr prior to incubation with compound for 1 hr,
followed by addition of Ni-chelate AlphaScreen donor beads (Perkin-Elmer) and Anti-Flag
AlphaLISA acceptor beads (Perkin-Elmer) at a final dilution of 1:1000 for 1 hr. Protein-protein
interaction assays were quantified using a PheraStar plate reader with excitation at 680 nm
wavelength and emission at 615 nm in 20 uL volumes in an uncoated, white, low-volume, 384-
well plate (Corning). Assayswere performed in a buffer containing 50mMMOPS (pH 7.25), 50
mM NaCl, 10mM MgCl2, 1mM TCEP, with addition of 1mM ATP, 0.01% BSA, and 0.01%
Tween-20 immediately prior to the start of the assay. The protein-protein interaction assay for
the interaction between CDK2/Cyclin A and N-terminally Flag tagged CDC25A C431S
(331-524) was performed as above.
CDC25B phosphatase activity assay
Wild-type CDC25B (372-566) at 250 nM was incubated with 7 for 1 hr in buffer containing 50
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mMTris (pH 8.0), 50 mMNaCl, 1 mMTCEP, and 5%DMSO, followed by the addition of 500
nM pCDK2/Cyclin A. After 50 minutes at room temperature, the reaction was quenched by
adding 1:1 equivalents of 2x SDS-PAGE loading buffer. Reaction samples were separated on a
4-20% SDS gel 170 volts for 45 minutes. Proteins were transferred to nitrocellulose with a wet
electrotransfer system(BioRad) for 60minat 25volts. Subsequently, themembranewasblocked
with 5%BSA in Tris-buffered saline with 0.1% Tween-20 (TBS-T), and incubated overnight at
4 °C with anti-pT15-cdc2 monoclonal antibody (#9111, Cell Signaling Technology, 1:2000).
After washing, the membrane was incubated with an HRP conjugated anti-rabbit antibody
(1:10,000) and visualized.
Compound Synthesis*
All solvents and reagents (including compounds 1-6) were used as obtained from commercial
sources unless otherwise indicated. The 1H NMRs were taken on a Bruker Avance III 600MHz
orVarianMR400. Chemical shifts were reported in ppm relative to tetramethylsilane or residual
solvent signal. The mass measurements were determined on a Micromass LCT time-of-flight
mass spectrometer using positive mode and electrospray ionization. The exact mass
measurements were determined on Agilent Q-TOF time-of-flight mass spectrometer using
positive or negative ion mode and electrospray ionization. Analytical TLC was performed on
MerckTLCaluminumplates precoatedwith F254 silica gel 60 (UV, 254 nm, and iodine). Infrared
(IR) spectrawere recorded on Perkin-Elmer FT-IRSpectrumBXon neat powder and onlymajor
characteristic signals are reported.
2,6-difluoro-4-(methoxymethoxy)benzonitrile (6)
In 10 mL of DCMwere dissolved 1 g of 2,6-difluoro-4-hydroxybenzonitrile (6.45 mmol, 1 eq)
and 1 g ofDIPEA (7.74mmol, 1.2 eq). Then 0.571 g ofMOMCl (7.09mmol, 1.1 eq)were added,
and the reactionmixture was allowed to stand at r.t. overnight. Next day themixture was filtered
through 20 g of silica gel, eluting with DCM, and the solvent was evaporated.
Yield 1.28 g (100%). Colorless oil.
1H NMR (499.68 MHz, CDCl3): δ = 3.49 (s, 3H, MeO), 5.21 (s, 2H, CH2), 6.72 (d,
2H, 3J(H-F) = 9.95 Hz).
19F NMR (470.12 MHz, CDCl3): δ = 103.0 (d, 3J(H-F) = 9.95 Hz).
*All compound sythesis was performed by Sergii Dudkin
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13C NMR (150.92 MHz, CDCl3): δ = 56.75 (OMe), 85.44 (t, 2J(C-F) = 19.8 Hz, C-1),
94.75 (OCH2O), 100.8 (dd, 2J(C-F) = 23.1 Hz, 4J(C-F) = 2.2 Hz, CHAr-3, CHAr-5), 109.6
(CN), 162.9 (3J(C-F) = 13.2 Hz, C-4), 164.2 (dd, 1J(C-F) = 259.1 Hz, 1J(C-F) = 6.7 Hz).
IR (ATR, cm–1): ṽ = 3098 (w), 2942 (w), 2836 (w), 2240 (w), 2156 (w), 2082 (w),
2008 (w), 1634 (s), 1574 (m), 1496 (m), 1454 (m), 1350 (m), 1308 (w), 1218 (m),
1158 (m), 1140 (s), 1076 (s), 1044 (s), 1004 (s), 920 (s), 842 (m), 716 (m), 688 (w).
2-[(2-Cyano-3-fluoro-5-hydroxyphenyl)thio]ethanesulfonic acid, sodium salt (7)
Into a 25-mL round bottom flask were placed 0.150 g of 2,6-difluoro-4-(methoxymethoxy)
benzonitrile 9 (0.753 mmol, 1 eq), 0.124 g of sodium 2-mercaptoethanesulfonate (0.753 mmol,
1 eq), 0.160 g of sodium carbonate (1.51 mmol, 2 eq) and 1.5 mL of DMF. The reaction mixture
was stirred at 100 °C under argon for 3 days. Then DMF was evaporated, the residue was
dissolved in water and treated with 0.78 mL of conc. HCl. After ½ h the acid was removed in
vacuum, the residue was dissolved in methanol and evaporated with 2 g of silica gel. Column
chromatography was performed with 7 g of silica gel, eluting first with pure EtOAc, then with
EtOAc/EtOH 5:2.
Yield 0.068 g (30%). Off-white solid.
1H NMR (600.13 MHz, DMSO-d6): δ = 2.72 (t, 2H, 3J = 8.16 Hz, CH2-SO3Na), 3.24
(t, 2H, 3J = 8.16 Hz, CH2-S), 6.61 (dd, 1H, 3J(H-F) = 11.33 Hz, 4J = 1.59 Hz, H-4), 6.71
(d, 1H, 4J = 1.59 Hz, H-6), 11.37 (br s, 1H, OH).
13C NMR (150.92 MHz, DMSO-d6): δ = 27.7 (CH2-S), 50.0 (CH2-SO3Na), 89.3 (d, 2J
(C-F) = 17,6 Hz, C-2), 100.4 (d, 2J(C-F) = 22.1 Hz, CH-4), 109.7 (CH-6), 112.9 (CN),
144.7 (d, 3J(C-F) = 2.2 Hz, C-1), 163.5 (d, 3J(C-F) = 13.2 Hz, C-5), 164.8 (d, 1J(C-F) = 239.5
Hz, C-3).
19F NMR (282.38 MHz, DMSO-d6): δ = –105.9 (d, 1F, 3J(H-F) = 11.33 Hz).
HRMS (ESI): Calcd. for C9H7FNO4S2 [M-Na]–: 275.9806, found: 275.9813.
3-[(2-Cyano-3-fluoro-5-hydroxyphenyl)thio]propane-1-sulfonic acid, sodium salt (8)
This compound was prepared similarly to 2-[(2-Cyano-3-fluoro-5-hydroxyphenyl)thio]
ethanesulfonic acid, sodium salt (7), starting from 0.150 g of 2,6-difluoro-4-
(methoxymethoxy)benzonitrile (0.753 mmol, 1 eq) and 0.134 g of sodium 3-
mercaptopropanesulfonate (0.753 mmol, 1 eq).
Yield 0.154 g (65%).
1H NMR (600.13 MHz, DMSO-d6): δ = 1.86-1.95 (m, 2H, CH2), 2.56 (t, 2H, 3J = 6.97
Hz, CH2-SO3Na), 3.14 (t, 2H, 3J = 6.97 Hz, CH2-S), 6.44 (d, 1H, 3J(H-F) = 9.54 Hz,
H-4), 6.60 (s, 1H, H-6), 8.31 (br s, 1H, OH).
19F NMR (470.12 MHz, DMSO-d6): δ = 106.87 (s, 1F).
13C NMR (150.92 MHz, DMSO-d6): 24.7 (CH2), 30.52 (CH2-S), 49.87 (CH2-SO3Na),
87.1 (C-2), 100.5 (CH-4), 110.6 (CH-6), 113.6 (CN), 144.1 (C-1), 162.3 (C-5), 165.0
(d, 1J(C-F) = 253.1 Hz, C-3).
HRMS (ESI): Calcd. for C10H9FNO4S2 [M-Na]–: 289.9963, found: 289.9979.
80
Notes
This chapter is based on the publication "Inhibition of CDC25B phosphatase through disruption
of protein-protein interaction", (2014) ACSChemBiol by George Lund, Sergii Dudkin, Dmitry
Borkin,WendiNi, JolantaGrembecka, andTomekCierpicki.GeorgeLundandTomekCierpicki
designed the experiments; George Lund performed the NMR experiments, crystallography
studies and in vitro assays; Sergii Dudkin and Dmitry Borkin synthesized compounds 6, 7, and
8; Wendi Ni helped with protein expression and purification; Jolanta Grembecka advised the
project and helped edit the manuscript.
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Appendix Figure 3.A1. Synthesis of compounds 7 and 8. Schematics and yields are shown
for the synthesis of compounds 7 and 8.
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Appendix Figure 3.A2. Electron density for compounds 1 and 7 before and after refinement.
A) Fo-Fc electron density map cut at 3.0 σ for compound 1 prior to molecular replacement.
B) 2Fo-Fc map cut at 1.5 σ for compound 1 after refinement. C) Fo-Fc map cut at 2.0 σ for
compound 7 prior to molecular replacement. D) 2Fo-Fc map cut at 1.0 σ for compound 7
after refinement.
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PDB code  
CDC25B-1 
4WH7 
CDC25B-7 
4WH9 
Data collection   
Space group P212121 P212121 
Cell dimensions   
    a, b, c (Å) 51.2, 71.4, 73.5 51.7, 71.5, 73.9 
Resolution (Å) 1.62 (1.65-1.62) 1.50 (1.58-1.50) 
Unique reflections 35426 (1746) 44620 (6450) 
Rsym  0.154 (0.467) 0.081 (0.538) 
I / σI 28.6 (2.3) 14.3 (3.8) 
Completeness (%) 90.7 (90.2) 100.0 (100.0) 
Redundancy 2.3 (2.2) 7.3 (7.3) 
   
Refinement   
Rwork / Rfree (%) 15.7 / 19.8 12.8 / 15.2 
No. atoms   
    Protein 1511 1528 
    Water 287 296 
Mean B-factors (Å2) 24.4 20.3 
R.m.s. deviations   
    Bond lengths (Å) 0.011 0.012 
    Bond angles (°) 1.187 1.928 
Ramachandran plot   
Most favored regions 
(%) 
97.2 97.3 
Additional allowed 
regions (%) 
2.8 2.7 
 
Appendix Table 3.A1. Crystallographic data collection and refinement statistics.
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Chapter 4
High-throughput screening to identify inhibitors of the CDC25B-CDK2/Cyclin A
protein-protein interaction
4.1 Abstract
Aberrant activation of the CDK2/Cyclin A complex by the phosphatase CDC25B in cancer has
resulted in significant drug discovery efforts to inhibit CDC25B activity. To date, all high-
throughput screeningefforts targetingCDC25Bhaveusedartificial substrates inorder to identify
inhibitors of CDC25B enzymatic activity. As discussed in Chapter 1, the inhibitors identified in
such screens have several drawbacks. In order to identify new classes of CDC25B inhibitors,
alternative screening methods must be developed.
Here, we describe the development of multiple assays for the quantification of the
CDC25B-CDK2/Cyclin A protein-protein interaction (PPI). These assays were used to screen
for smallmolecule inhibitors of theCDC25B-CDK2/CyclinA interaction in three separate high-
throughput screening campaigns at the University of Michigan Center for Chemical Genomics.
From these screening campaigns, we identified several inhibitors of theCDC25B-CDK2/Cyclin
A PPI with activity in vitro and for one compound, in pancreatic cancer cells. Importantly, we
have established a novel, high-quality screening assay for the identification of CDC25B-CDK2/
Cyclin A PPI inhibitors. This assay represents a novel approach to the identification of new
CDC25B inhibitor classes.
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4.2 Introduction
As described in Chapter 1, the CDC25 phosphatases are critical regulators of the cell cycle and
are overexpressed inmany types of cancer. Furthermore,many studies detailed inChapter 1 have
implicated CDC25B as a target for therapeutic intervention. Previous attempts to identify
CDC25B inhibitors using high-throughput screening (HTS) efforts have been exclusively
focused on the use of artificial substrates to observe inhibition of CDC25B enzymatic activity1–
4. As discussed in Chapter 1, this approach has been shown to have several limitations. First, the
reactivity of the catalytic cysteine has led to the discovery of reactive covalent modifiers of
CDC25s that have been unsuccessful as therapeutic candidates5,6. Second, several previously
characterized inhibitors of CDC25B inhibit its cellular activity indirectly through the generation
of intracellular reactive oxygen species7–10, which has many other cellular effects outside of
CDC25B inhibition11. Third, the active sites of the CDC25s are shallow, and do not confer
substrate recognition12. For these reasons, new approaches for the discovery of small molecule
inhibitors targeting this class of enzymes are required.
Recently, the concept of “gray box” screening approach to discovery of small molecule
inhibitors or activators has been introduced13,14. Gray box screening involves reconstituting an
entire biologically relevant system in a biochemical assay for use in inhibitor screening. This
includesusingentire protein complexeswith their relevant cofactors, phosphorylation states, etc.
The advantage of the “gray box” approach over a typical biochemical assay is to better
recapitulate the entire biological system. The “gray box” screening concept is also contrasted
with cell-based screening approach, sometimes referred to as “black box” screening. A
Limitation of cell-based screening is the significant effort required to determine the molecular
target of identified hits and determine their mechanism of action.
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“Gray box” screening represents an attractive approach to target CDC25B. As detailed
in Chapter 1, a primary pitfall of previous assays targeting CDC25B was the use of artificial
substrates to target CDC25B enzymatic activity. Reconstituting the entire biological system of
CDC25B and its substrate CDK2/Cyclin A removes the bias towards identification of active site
inhibitors. As characterized in Chapter 2, recognition of the CDK2/Cyclin A complex by
CDC25B is mediated primarily through two sites distant from the active site. The gray box
screening approach has the potential inhibit substrate recognition by targeting these PPI sites.
Here, we describe our efforts to identify and optimize a high-quality “gray box” screening assay
for theCDC25B-CDK2/CyclinA interaction.Wehave iteratively optimizedmultiple assays and
tested them in three distinct HTS campaigns. Ultimately, we used the optimized assay in large-
scale screen in order to identify small molecule inhibitors of the CDC25B-CDK2/Cyclin A PPI.
4.3 Biochemical assays and high-throughput screening strategy
Several biochemical assays are compatiblewith “gray box” screening to identify protein- protein
interaction (PPI) inhibitors. Two assays have been frequently used to quantify the extent of the
PPI between proteins15–17. One of these is the Amplified Luminescent Proximity Homogeneous
Assay, or AlphaLISA assay16,18. This assay uses the transfer of a singlet oxygen species between
two fluorophore-conjugated beads to detect the proximity of the two fluorophores. Upon
fluorescent excitation, the singlet oxygen is released from the donor bead. If an acceptor bead is
within approximately 1000Åof the donor, the transfer of the singlet oxygen induces the acceptor
bead to fluoresce. When conjugated with antibodies, the AlphaLISA reagents can quantify the
interaction of two proteins of interest.
A second frequently used assay for PPI quantification is the homogeneous time-resolved
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fluorescence (HTRF) assay19,20. Conceptually, the HTRF assay is similar to the AlphaLISA
assay. Antibody-conjugated fluorescent beads recognizing proteins of interest are used to
quantify the extent of the PPI. The primary difference between the two assays is the fluorescent
inductionmechanism of the acceptor fluorophore. Instead of the reactive singlet oxygen species
used in the AlphaLISA assay, the HTRF assay relies on fluorescent resonance energy transfer
(FRET) to quantify bead proximity. HTRF energy transfer occurs most efficiently at distances
of less than 100 Å.
The development of a high-quality biochemical assay for HTS depends on the rigorous
assessmentof its statistical robustnessduringassaydevelopment and through theHTScampaign.
Several statistical measures have been established as important metrics for assessing the quality
of a given assay. We primarily employed three of these measures: the signal-to-noise (S/N), the
coefficient of variation (CV)21, and the Z-factor22. In our assays, the S/N is calculated as the ratio
of the positive control measurement with all assay components to the negative control
measurement without protein reagents. The second measure used is the CV, which is a
standardized measure of the variability between measurements and reported as a percentage.
Lower CVs indicate lower measurement variability. The third statistical metric, the Z-factor, is
widely used for determining the quality of a high-throughput assay. The Z-factor takes into
account both the S/N between positive and negative controls as well as the standard deviations
of both controls (Equation 1). With an upper limit of 1, an assay with a Z-factor greater than 0.5
is considered an acceptable assay22.
Equation 4.1
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The HTS approach used in in our screening campaigns described below employed a 3
stage format: aprimary screening stagewith a singlepointmeasurementper compound, followed
by a confirmation screening stage where selected compounds from the primary screen were
retested, and a final dose-response stagewhere compounds titrationswere performed.Hits in our
assays were defined as compounds demonstrating inhibition greater than 3 standard deviations
compared to plate negative controls (hereafter called 3SD).
4.4 HTS-1: AlphaLISA-based high-throughput screening for inhibitors of CDC25B-
CDK2/Cyclin A
4.4.1 Optimization of the AlphaLISA assay for HTS
To identify inhibitors of the CDC25B-CDK2/Cyclin A protein-protein interaction, we tested
both theAlphaLISAandHTRFassays. For assay development,we designed aC-terminally Flag
tagged, catalytically inactive CDC25Bphosphatase domainmutant C473S (CDC25B-Flag) and
an N-terminally 6xHis tagged CDK2 protein in complex with the CDK2 binding domain of
Cyclin A (His-CDK2/Cyclin A). Protein constructs are detailed in Table 4.A1. We first
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Figure 4.2.Design of the AlphaLISA assay.Schematic of theCDC25B-CDK2/CyclinAAlphaLISA
assay.
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optimized the AlphaLISA assay using Ni-chelate Alpha donor beads and anti-Flag AlphaLISA
acceptors beads (Figure 4.2). Compared to buffer controls, the optimizedAlphaLISA assaywith
our protein reagents produced a10-foldS/N.Wealso attempted todevelop theHTRFassayusing
anti-6xHis europium cryptate donor beads and anti-Flag XL-665 acceptor beads. However,
development of the HTRF assay was unsuccessful. We therefore moved ahead with validation
of the AlphaLISA assay. In competition experiments with untagged CDK2/Cyclin A complex,
the AlphaLISA signal showed dose-dependent inhibition of the CDC25B-Flag and His-CDK2/
Cyclin A PPI. As CDC25B dephosphorylates Thr14 and Tyr15 on CDK2, we assessed whether
or not this modification affected the CDC25B-CDK2/Cyclin A PPI in our assay. Titration with
either untagged CDK2/Cyclin A or untagged pT14-pY15-CDK2/Cyclin A disrupted the
AlphaLISA signal in a dose-dependentmatter with similar affinities (Figure 4.3). This indicated
that the PPI between CDC25B and CDK2/Cyclin Awas not affected by CDK2 phosphorylation
state at Thr14 and Tyr15. Once our AlphaLISA assay was validated for sensitivity to inhibition
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Figure 4.3. Validation of the HTS-1 AlphaLISA assay. Left: Competition of untagged
pT14pY15-CDK2/Cyclin A (red) and unphosphorylated CDK2/Cyclin A (black) in the
AlphaLISA assay. Right: Pre-HTS assay statistics for the AlphaLISA assay.
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by untagged CDK2/Cyclin A, the assay was optimized for HTS. The S/N, CV, and Z-factor for
a single 384-well control plate using our AlphaLISA assay under HTS conditions was 9.0, 1.4%
and 0.92 respectively, indicating that our assay was of high quality.
4.4.2 Primary screening for HTS-1
In the primary screening stage, we screened 64,640 compounds from the compound library of
the University of Michigan’s Center for Chemical Genomics (UM-CCG). In order to allow for
the identification of potentially weak inhibitors, we screened using a relatively high compound
concentration of approximately 35 µM. Compared to assay plate controls, the AlphaLISA assay
performed well under HTS conditions with an average Z-factor of 0.80; data from an example
16 plate day of screening is shown in Figure 4.4. Despite the high performance of the assay with
respect to the controls, we observed a very high hit rate of 17.8% as determined by 3SD for the
primary screen, resulting in 11,514 hit compounds.
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Figure 4.4. HTS-1 performance. High-throughput screening performance of 16 384-well
plates (plate numbers 5318-5333) from a single day of screening. A scatter plot containing
positive controls (green), negative controls (red), and compound wells (black) is shown.
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Due to the high hit rate in the primary screen, additional analysis was required to select
compounds for progression to the confirmation stage. First, the 11,514 hit compounds defined
in the primary screen were clustered by similarity as detailed in themethods section to eliminate
chemically redundant compounds.Themost potent compound fromeachclusterwas selected for
further analysis. The 4039 compounds remaining after clustering were analyzed by manual
inspection to further eliminate redundant scaffolds and to remove quinone-containing
compounds for the reasons detailed inChapter 1.Aftermanual analysis, the top3200 compounds
with the strongest inhibitionwere selected for advancement to the confirmation screening stage.
4.4.3 Confirmation screening for HTS-1
Confirmation screening was conducted by testing compounds in two assays, the AlphaLISA
assay used for the primary screening stage as well as a control AlphaLISA counter screen. The
AlphaLISA counter screening assay was developed as a method to eliminate compounds that
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Figure 4.5. Primary and counter screening assays. Left: schematic of inhibition in the
AlphaLISA primary screening assay by small molecule inhibitors. Right: schematic of the
AlphaLISA-based counter screening method for the elimination of assay interfering
compounds.
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potentially interferewith theAlphaLISAassay. To this end,wedesigned a protein constructwith
aN-terminal 6xHis tag, theCDC25Bcatalytic domain, and aC-terminal Flag tag (His-CDC25B-
Flag) as described in Table 4.A1. This protein was then used in the AlphaLISA assay in place of
the CDC25-Flag and His-CDK2/Cyclin A protein combination used in the primary assay. Since
the tags in the His-CDC25B-Flag counter screening assay cannot be separated, any decrease in
AlphaLISAsignal observed in this assaymust be due to compound interference (Figure 4.5). The
3200 compounds selected from the primary screening stage were tested using both assays in
duplicate at 35µMconcentration.Of the3200compounds, 2023 that showedactivitygreater than
20% in the primary assay were selected for further analysis. Of this set, the 360 compounds with
at least 20% more inhibition in the primary assay than in the counter screening assay were
selected for thedose-response stage.Theboundedbox inFigure4.6 showsavisual representation
of compound selection.
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4.4.4 Dose response and follow up for HTS-1
For the final dose-response stage, the360compounds selected fromtheconfirmation screenwere
tested in duplicate in titration experiments using the AlphaLISA primary assay. Titration
experiments were performed in an 8-point, 2-fold dilution series format starting at 150µM
concentration, followed by sigmoidal curve fitting analysis. Of the 360 compounds tested, 63
exhibited dose-dependent inhibitionof theAlphaLISAsignalwith an IC50 greater than50µMand
were considered as active hits. A breakdown of HTS-1 results is given in Figure 4.7.
Twenty-six of these active compounds were ordered from commercial sources for
retesting. Of the compounds dissolved from fresh powder, 18 showed activity similar to or
greater than that observed during the dose response experiments. The validated compounds had
a variety of scaffolds, and included seven compounds with IC50 of less than 15µM (Table 4.1).
The most potent inhibitor identified was compound CCG-17950 with an IC50 of 6 µM (Figure
4.8A).
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Figure 4.7. Breakdown of HTS-1 results
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Table 2. Most potent validated hits from HTS-1
Name Structure Percent primary
Percent
secondary
Percent 
counterscreen
IC50 
DR
(uM)
IC50
Fresh
(uM)
CCG-17950 100.4 88.6 44.5 38.0 5.9
CCG-125215 92.4 101.8 49.8 25.1 8.9
CCG-28155 92.3 96.1 11.8 3.9 14.5
CCG-172232 84.0 94.9 31.1 66.1 15.5
CCG-17560 69.7 77.8 17.4 79.4 17.4
CCG-106526 72.7 88.9 48.3 128.8 18.2
Table 4.1. Most potent hits validated from HTS-1.
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4.4.5 Characterization of CCG-17950
The most potent validated hit compound obtained from HTS-1 was 7-chloro-5-((4-(2-
methoxyphenyl)piperazin-1-yl)methyl)quinolin-8-ol, or CCG-17950 (Figure 4.8A). In order to
address the mechanism of inhibition for CCG-17950, we used NMR to determine the protein to
which it binds. No chemical shift perturbations were observed on a 1H15N-HSQC spectrum for
CDC25B, indicating that it was not the target of CCG-17950. However, ligand-detected NMR
experiments indicated that CCG-17950 binds to the CDK2/Cyclin A complex (Figure 4.8B). In
addition to its ability to disrupt the CDC25B-CDK2/Cyclin A protein-protein interaction,
titration with CCG-17950 inhibited the dephosphorylation of pTpY-CDK2/Cyclin A by
CDC25B in vitro (Figure 4.8C).
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Figure 4.8.CCG-17950 binds to CDK2/Cyclin A and inhibits its dephosphorylation in vitro.A)
Inhibition of the CDC25B-CDK2/Cyclin A PPI by CCG-17950 in an AlphaLISA experiment
(structure inlaid). B) 1H 1D NMR spectrum for CCG-17950 alone (red) or WaterLOGSY
spectrum of CCG-17950 in the presence of CDK2/Cyclin A. C) In vitro phosphatase assay
utilizing phosphorylated CDK2/Cyclin A as a substrate for CDC25B in the presence or absence
of CCG-17950. Remaining phosphorylated CDK2/Cyclin A is detected by western blot.
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Because CDC25B is highly overexpressed in pancreatic cancers, we tested the effect of
CCG-17950on the viability of pancreatic carcinomacell lineMIAPaCa-2.MIAPaCa-2 cell line
expresseshigh levelsofCDC25Bandhasbeenpreviouslybeenshown tobesensitive toCDC25B
inhibitors23. In a dose-dependent manner, MIA PaCa-2 cells showed slower growth upon
treatment with CCG-17950, with greater than fifty percent growth inhibition at 25 µM (Figure
4.9A). We further examined the CDK2 phosphorylation status upon compound treatment in
order to examine whether the reduction in cell growth was due to the inhibition of CDK2
dephosphorylation. CCG-17950-treated cells showed a marked inhibition of CDK2
dephosphorylation as compared to vehicle control (Figure 4.9B). The inhibition of CDK2
dephosphorylation by CCG-17950 closely resembled that of the CDK2 kinase inhibitor
NU-6102, which arrests cells in G2 phase24. Analysis of the cell cycle upon treatment with
CCG-17950 revealed a dose-dependent arrest in the S and G2 phases as compared to vehicle
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Figure 4.9. CCG-17950 inhibits CDK2 dephosphorylation and causes cell cycle arrest in vivo.
A) MTT assay showing cell viability of MIA PaCa-2 cells in the presence of CCG-17950,
normalized to DMSO control (gray). B) Western blot showing CDK2 phosphorylation in
response to treatment with CCG-17950 in synchronized MIA PaCa-2 cells. The CDK2 kinase
inhibitor NU-6102 is shown as a pseudo-positive control. C) Percentage cell distribution for
different cell cycle phases in response to CCG-17950 treatment of synchronized MIA PaCa-2
cells. NU-6102 is shown as a pseudo-positive control.
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controls (Figure 4.9C). These results indicate that CCG-17950 is an inhibitor of the CDC25B-
CDK2/CyclinA interaction invitro and inhibitsCDK2dephosphorylation in cells, leading to cell
cycle and growth arrest in pancreatic cancer cells.
4.5HTS-2: Improvements upon theAlphaLISA assay and re-screening of a subset library
4.5.1 Redesigning the AlphaLISA assay
Two observations fromHTS-1 prompted a redesign of theAlphaLISA assay. First, the very high
hit rate of theHTS-1 assay severely limited our ability to followupwith potential hit compounds.
Second, our characterization of validated hits from HTS-1 found that the inhibition of several
compounds was lost upon the addition of ATP. Since ATP binds the active site of CDK2, we
inferred that the loss of activity of these compounds was due either to competition with ATP for
the active site, or to any structural changes associated with ATP binding.
We made several modifications to the AlphaLISA assay to address the high hit rate and
the ATP sensitivity. First, we optimized the assay in the presence of ATP and Mg, which is
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Figure 4.10.AlphaLISAassaymodifications forHTS-2.Left: Inhibition in theAlphaLISAassay
by CCG-21303 in the presence (red) and absence (black) of 2mM ATP. Right: Disruption of
AlphaLISA signal upon titration with either the CDC25B catalytic domain (red) or
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required for proper ATP binding25. At saturating concentrations of ATP!Mg, compounds
showing ATP-dependent inhibition no longer had any effect in the assay (Figure 4.10). To
attempt to reduce the hit rate, we decided to alter our CDC25B protein construct. Our initial
CDC25B protein construct used for HTS-1 contained only the CDC25B catalytic domain,
without the C-terminal unstructured region. Further analysis of the literature26 and our own
characterization of this region (see Chapter 2) revealed that several residues contribute to the
CDC25B-CDK2/CyclinA interaction.Wehypothesized that by including thisC-terminal region
wemight increase the affinity of the PPI and limit the number of compounds affecting our assay.
We therefore redesigned our CDC25B construct to include the 9 remaining residues in the C-
terminus ofCDC25B (CDC25B_long-Flag).We also added a 5 residue gly-ser linker prior to the
C-terminal Flag tag to separate the Flag tag from the C-terminal residues of CDC25B. In the
redesigned AlphaLISA assay, titration with untagged CDC25B containing the additional C-
terminal residues (CDC25B_long) showed a 50-fold increase in potency compared to the
untagged construct used in HTS-1 (CDC25B), confirming that the inclusion of these residues
significantly increases binding affinity (Figure 4.10).
Ultimately, the new AlphaLISA assay increased the S/N over 10-fold compared to the
assay used in HTS-1. Testing of a single 384-well control plate using our newAlphaLISA assay
under HTS conditions produced a S/N of 125, a CV of 6.9%, and a Z-factor of 0.79, indicating
that the revised AlphaLISA assay was high quality.
4.5.2 Primary screening for HTS-2
Using our revised AlphaLISA assay, we screened a 20,000 compound subset of the UM-CCG
library screened previously in HTS-1. As in HTS-1, we screened using a relatively high
101
compoundconcentration around35µMtoallow for identificationof low-potency inhibitors. The
AlphaLISA assay performed well under high-throughput screening conditions with an average
Z-factor of 0.70. Similarly toHTS-1,we observed a high hit rate of 29.6% for the primary screen,
resulting in 5,918 hit compounds. Of these compounds, 1,500 were selected for advancement to
the confirmation screening stage as described in Table 4.A2.
4.5.3 Confirmation screening for HTS-2
Confirmation screening was conducted with both the primary AlphaLISA assay as well as the
control AlphaLISA counter screen as described in HTS-1. The 1500 compounds selected from
the primary screening stage were tested in both assays in duplicate at 35 µM concentration
(Figure 4.11). Of these compounds, the 246 that showed activity greater than 5% inhibition in
the primary than in the counter screening assay were considered for further analysis. The 246
remaining compoundswere inspectedmanually to cluster redundant compounds, and the top120
compounds were selected for advancement to the dose-response stage.
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4.5.4 Dose response and follow up for HTS-2
The 120 compounds selected for the dose response screening stage were tested in duplicate
titration experiments using the HTS-2 primary assay. Compounds were titrated in an 8-point, 2-
fold dilution series format starting at 150µM concentration. Of the 120 compounds tested, 23
compounds exhibiting dose-dependent inhibition with an IC50 greater than 50µM and were
considered active inhibitors. Figure 4.12 gives a breakdown of HTS-2 results.
Of the 23 compounds identified as active in the dose response screening stage, six
compounds were ordered from commercial sources. Four of the ordered compounds showed
comparable activity to that determined during dose response screening, with IC50 between 5 and
15 µM (Table 4.2). One of these four inhibitors was the compoundCCG-18861, which inhibited
the CDC25B-CDK2/Cyclin A interaction with an IC50 of 15 µM (Figure 4.13)
Figure 4.12. Breakdown of HTS-2 results.
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Table 4.2. Most potent hits validated from HTS-2.
Name Structure Percent primary
Percent
secondary
Percent 
counterscreen
IC50 
DR
(uM)
IC50
Fresh
(uM)
CCG-28496 56.6 49.5 5.9 28.8 6.9
CCG-21280 41.1 52.9 13.0 49.0 7.2
CCG-20311 52.4 80.6 17.2 45.7 11.6
CCG-18861 87.9 79.0 15.0 13.8 14.9
4.5.5 Characterization of CCG-18861
Weselected the compoundCCG-18861, or 2-(4-bromophenyl)-6-chloroquinoline-4-carboxylic
acid, for further characterization. Similar to the characterization of CCG-17950, we employed
NMR to identify the target of CCG-18861. No chemical shift perturbations were observed on a
1H15N-HSQC spectrum forCDC25B, but ligand-detectedNMRexperimentswithCDK2/Cyclin
A indicated that CCG-18861 binds to the CDK2/Cyclin A complex (Figure 4.13). To further
understand the binding mode of this compound, we crystalized the CDK2/Cyclin A complex in
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the presence of CCG-18861 (Figure 4.13). Crystals soaked with compound reproducibly
produced unaccounted for electron density in the RxL-binding pocket on Cyclin A, a site known
tobe important for substrate recognitionof theCDK2/CyclinAcomplex27.This site has alsobeen
hypothesized to interactwith theCDC25BC-terminal tail26. Superimposition of theCCG-18861
Fo-Fcelectrondensitymapontoacrystal structureofCDK2/CyclinAbound toaCDK2substrate
containing the RxL motif28 shows that portions of the CCG-18861 density overlap with the
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Figure4.13.CCG-18861binds to theRxLmotif onCyclinAand inhibitsCDC25B-CDK2/Cyclin
A. A) Inhibition of the CDC25B-CDK2/Cyclin A PPI by CCG-18861 in an AlphaLISA
experiment (structure inlaid). B) Crystal structures in the presence (left) and absence (right) of
CCG-18861. 2Fo-Fc density map cut at 1.0σ is shown as a gray mesh; Fo-Fc difference map cut
at 2.5σ is shown as a green mesh. I213 is encircled with a dotted ellipse. C) 1H 1DNMR spectra
for CCG-18861 alone (green) and saturation transfer difference (STD) experiments in the
presence of either wild-type CDK2/Cyclin A (red) or CDK2/Cyclin A complex with Cyclin A
I213E mutation (blue).
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peptide (Figure 4.13). Specifically, the electron density for CCG-18861 clearly overlaps the
leucine of the RxL peptide, which has been previously demonstrated to be critical for the
interaction between RxL-containing peptides and the Cyclin A binding pocket29. Although the
observed electron density was not sufficiently well defined to accurately determine the structure
of CCG-18861 in this site, we hypothesized that the inhibitory activity of CCG-18861 was due
to competition for this site with CDC25B. To address this hypothesis, we mutated a key
hydrophobic residue in this pocket to a glutamic acid (I213E). As indicated by STD NMR
experiments, binding of CCG-18861 to the mutant complex was significantly reduced (Figure
4.13). To ensure this mutation did not affect the structure of the CDK2/Cyclin A complex, we
determined the crystal structure of the mutant and found no significant changes between the
mutant and the wild-type structures (not shown). Combined, these data indicates that
CCG-18861 binds to the CDK2/Cyclin A complex in the RxL-binding pocket of Cyclin A and
disrupts the PPI with CDC25B (Figure 4.14).
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Figure 4.14. Disruption of the CDC25B-CDK2/Cyclin A PPI by CCG-18861. Model of the
disruption of CDC25B-CDK2/Cyclin A by CCG-18861 competing with CDC25B for the RxL-
binding motif.
106
4.6 HTS-3: Optimization of an HTRF-based assay for high-throughput screening
4.6.1 Design of the HTRF assay
Due to the high hit rate from both HTS-1 and HTS-2 AlphaLISA-based screens, we decided a
new,more robust assaywas required. For this reasonwe developed theHTRF assay. Though the
energy transfer in the HTRF assay requires 10-fold shorter distance between donor and acceptor
when compared to the AlphaLISA, the HTRF assay has several advantages. Primarily, the
europiumcryptate donorhas a long fluorescent lifetime in the rangeofµs-ms30, compared tomost
fluorescent organic compounds that have fluorescent lifetimes in the nanosecond range30. By
incorporating a delay between donor excitation and acceptor detection, the HTRF assay is less
sensitive to fluorescent compounds.
Asmentioned above, we tested both AlphaLISA andHTRFwith our CDC25B-Flag and
His-CDK2/Cyclin A constructs during HTS-1 optimization and observed signal for only the
AlphaLISA assay. Because the HTRF requires shorter distance between donor and acceptor
beads, this result indicated that the protein tag orientations used were sufficiently close for
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Figure 4.15. Development of the HTRF-based high-throughput screening assay for CDC25B-
CDK2/Cyclin A. Left: schematic of the HTRF assay showing both tag orientations tested on the
left, and the final assay configuration to the right. Right: Titration of untagged CDC25B_long
competitor in HTRF assays for both tag configurations.
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AlphaLISA, but not close enough for HTRF. Previously published computational models
suggested that the N-terminus of CDC25B is close to the C-terminus of CDK231, and therefore
we designed new protein constructs for use in the HTRF assay with an N-terminally Flag tagged
CDC25B and a C-terminally 6xHis tagged CDK2 in complex with Cyclin A (Flag-
CDC25B_long and CDK2-His/Cyclin A, Table 4.A1). Using these protein constructs we
observed HTRF signal, demonstrating that the new protein tag orientations were sufficiently
close for FRET to occur (Figure 4.15).
We titrated the HTRF assay with either untagged CDC25B or untagged CDC25B_long
to ensure the HTRF assay was sensitive to disruption by protein competitors. Both of the
competitors exhibited dose-dependent inhibition of theHTRF signalwith IC50 of 2.1 µMand128
nM for CDC25B and CDC25B_long respectively (Figure 4.16). After validation, the HTRF
assay was tested under HTS conditions using a control plate as was done in HTS-1 and 2. With
a S/N, CV, andZ-factor of 9.9, 6.9%, and 0.87 respectively, theHTRF assaywas deemed a high-
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Figure 4.16. Validation of the HTRF-based for assay high-throughput screening. Left:
disruption of HTRF signal upon titration with either CDC25B (red) or CDC25B_long (black).
Right: pre-HTS assay statistics for the HTRF assay.
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quality assay with a similar performance to the AlphaLISA assays in HTS-1 and 2. In addition
to assessment using a control plate, we performed a small-scale screen of four plates from the
UM-CCG compound library to determine the hit rate for the HTRF assay. As the primary
problemwithour first twoHTScampaignswas thehighhit rate, testingHTRFassayperformance
with compounds was critical prior to large-scale screening. Importantly, the 3SD hit rate for this
small-scale screen was 2.5 %, a 7-fold reduction as compared to HTS-1 and a 12-fold reduction
as compared to HTS-2. Once the HTRF assay had demonstrated increased robustness, we
proceeded with large scale HTS.
4.6.2 Primary screening for HTS-3
The optimized HTRF assay was used to screen 103,780 compounds from the UM-CCG
compound library. To reduce the number of hits compared to HTS-1 and 2, we screened at a
slightly lower compound concentration of approximately 25 µM. The HTRF assay performed
well under high-throughput screening conditions as judged by the average Z-factor of 0.75. The
hit rate by 3SD for the entire screen was 0.9%, far lower than the 17.8% and 29.6% observed for
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Figure 4.17. HTS-3 performance. High-throughput screening performance of 16 384-well
plates (plate numbers 5318-5333) from a single day of screening. A scatter plot containing
positive controls (green), negative controls (red), and compound wells (black) is shown.
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HTS-1 and 2 respectively. A representative set of 16 plates from a single day of screening is
shown inFigure4.17.All 902hits asdefinedby3SDwere selected for the confirmation screening
stage. We additionally selected weaker hits with inhibition less than 3SD but greater than 12%,
adding 598 more compounds for a total of 1,500.
4.6.3 Confirmation screening for HTS-3
Compounds selected for the confirmation screening stage were retested at the same 25µM
concentration in triplicate in both theHTRF assay used in the primary screen and theAlphaLISA
assay as used in HTS-2. Of the 1,500 compounds screened in the confirmation stage, 71
compounds showed inhibition greater than 3SD in both assays. Again, in order to further explore
weaker compounds, we selected the top 49 compounds with inhibition less than 3SD but greater
than 5% in both the HTRF and AlphaLISA assays. A total of 120 compounds from the
confirmation screening were selected for progression to the dose-response screening stage. The
bounded box in Figure 4.18 shows a visual representation of compound selection.
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compounds tested in confirmation
screening. The green dotted box denotes
the 150 compounds selected for dose-
response experiments.
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Table 3. Most potent validated hits from HTS-2 
 
Name Structure Percent primary 
Percent 
secondary 
Percent 
counterscreen 
IC50 
DR 
(uM) 
IC50 
Fresh 
(uM) 
CCG-42172 
 
47.3 56.1 27.3 11.0 2.0 
CCG-30182 
 
21.2 9.8 8.23 95.5 10.9 
CCG-144491 
 
47.2 18.7 22.5 20.0 44.6 
CCG-111697 
 
17.5 13.4 6.0 55.0 48.4 
CCG-149631 
 
32.2 14.0 20.6 >150 65.4 
CCG-159120 
 
53.7 54.3 19.4 20.9 69.0 
 
  
Table 4.3. Most potent hits validated from HTS-3.
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4.6.4 Dose response and follow up for HTS-3
For the final dose-response stage, the 120 compounds selected from the confirmation screening
were tested in duplicate with a starting concentration of 150µM followed by an 8-point, 2-fold
dilution series. 46 compounds exhibiting greater than 50% inhibition at 150 µMwere considered
to be active hits for further study. A breakdown of HTS-3 is shown in Figure 4.19.
Of the 46 compounds considered active fromHTS-3, 28 were ordered from commercial
sources for retesting. Six of the ordered compounds had a similar or increased potency compared
to their activity in the dose-response experiments using compound from the original screening
library. These validated hits ranged from 2µM to 70µM in potency (Table 4.3). The two most
potent compounds identified were CCG-42172 and CCG-30182, with IC50 of 2.0 µM and 10.9
µM respectively.
Figure 4.19. Breakdown of HTS-3 results.
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4.6.5 Characterization of HTS-3 hits: CCG-42172 and CCG-30182
The most potent of the hits validated from HTS-3 was 4-(2,4-dichlorobenzyl)-N-(pyridin-3-
yl)-1,4-diazepane-1-carbothioamide, or CCG-42172. Freshly dissolved CCG-42172 from
commercial sources disrupted the CDC25B-CDK2/Cyclin A PPI with an IC50 of 2.0 µM (Figure
4.20). The freshly prepared commercially acquired compound was more than 20-fold more
potent as compared to compound from the UM-CCG screening library, indicating that
CCG-42172 might have undergone degradation or precipitation in the compound library over
time. NMR experiments with this compound show that CCG-42172 does not interact with
CDC25B, but interacts with the CDK2/Cyclin A complex (Figure 4.21).
The second most potent compound identified from HTS-3 was CCG-30182 (7-((3,5-
dimethoxyphenyl)amino)-6-(furan-2-ylmethyl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-
one). CCG-30182 inhibited the CDC25B-CDK2/Cyclin A PPI with a 10.9 µM IC50 when
prepared from fresh powder (Figure 4.20). The limited inhibition by CCG-30182 in both the
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Figure 4.20. Validated hits CCG-42172 and CCG-30182 identified in the HTRF-based high-
throughput screen. Left: inhibition of the CDC25B-CDK2/Cyclin A PPI by CCG-42172 in a
HTRF experiment (structure inlaid). Right: inhibition of the CDC25B-CDK2/Cyclin A PPI by
CCG-30182 (structure inlaid) in an HTRF experiment. IC50s are given for both compounds.
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primary and confirmation screens indicated that it was a relatively weak hit under the 25 µM
screening concentrations. The 95.5 µM IC50 derived from the dose-response experiments also
demonstrated that this compound was a relatively weak inhibitor; however, freshly ordered was
more than 8-fold more potent. CCG-30182 was also tested by NMR for binding to CDC25B or
CDK2/CyclinA.The 1H15N-HSQCexperiment demonstrated no binding toCDC25Bandwedid
notobservebinding toCDK2/CyclinA in1DSTD.Ofnote, one limitationof theSTDexperiment
is a need for a relatively fast dissociation rate, and therefore this experiment may not be suitable
to validate binding of more potent ligands. More extensive characterization of CCG-30182 is
needed in order to confirm its mechanism of action.
4.7 Discussion
Here,wedescribeour efforts todevelopahigh-quality “graybox” screeningassay for identifying
inhibitors of theCDC25B-CDK2/CyclinAPPI. This entailed the development and optimization
of three separate screening assays. We initially tested both AlphaLISA and HTRF-based assays
for the quantification of the CDC25B-CDK2/Cyclin A PPI. The AlphaLISA assay initially
proved to be more straightforward to develop, since no HTRF signal was observed using the
8.5 8.0 7.5 7.0
ppm
1H
STD
Figure 4.21. CCG-42172 binds to CDK2/
Cyclin A. 1H 1DNMRspectra for CCG-42172
alone (red) and saturation transfer difference
(STD) experiments in the presence of CDK2/
Cyclin A (blue).
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original protein constructs. As judged by the statistics of pre-HTS control experiments, the
AlphaLISAassaywashighly suitable forHTS.And though theassay itself performedwellduring
HTS-1 with an average Z-factor of 0.8, the utility of the AlphaLISA was limited by a very high
hit rate under compound screening conditions. The high hit rate of 17.8% in HTS-1 resulted in
a large number of hits (Figure 4.22), which required time consuming statistical and manual
analysis to select compounds for confirmation screening.
We attempted to reduce the hit rate by increasing the robustness of theAlphaLISA assay.
The extension of the CDC25B C-terminus to enhance affinity to CDK2/CyclinA and the
inclusion of ATP in this assay resulted in over a 10-fold increase in S/N as compared to the assay
used in HTS-1. Similarly to the HTS-1 assay, the HTS-2 AlphaLISAwas of high quality for use
in HTS as determined in our pre-HTS control experiments. We employed the HTS-2 assay to
screen a subset of the compound library including 20,000 compounds. Similar toHTS-1, the new
AlphaLISA assay performed well under screening conditions with a Z-factor of 0.70, but the
29.6% hit rate indicated that the new assay was still highly susceptible to interference (Figure
4.22).
HTS-1 HTS-3
17.8%
0.9%
Not hits
Primary hits
HTS-2
29.6%
Figure 4.22. Comparison of the hit rate between HTS-1, HTS-2, and HTS-3. Pie chart of the hit
rate from the primary screening campaigns for HTS-1, 2, and 3. Hits are defined as compounds
with inhibition greater than 3 standard deviations compared to plate negative controls.
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In order to address the high hit rate in our first two screens, we revisited the HTRF assay.
Optimization of the HTRF assay for HTS-3 was comparatively more extensive due to required
protein construct redesigns. The HTRF assay we developed proved to be of high quality as
determined in our pre-HTS control experiments. In addition to the use of an entirely different
assay, we reduced the compound concentration by 30% in order to limit compound interference.
Interestingly, the performance of the HTRF assay during HTSwas nearly identical to that of the
first two screens, as judged by its Z-factor of 0.75. However, the 0.9% hit rate indicated that this
assay was much more robust for compound screening and less susceptible to false positives
(Figure 4.22). The increased robustness of this assay allowed us to screen a relatively large
library, including over 100,000 compounds. Importantly, the low hit rate of the HTRF assay
allowed for more thorough follow up studies of HTS hits.
Through our three high-throughput screening campaignswe identified and characterized
several hit compounds: CCG-17950, CCG-18861, CCG-42172, and CCG-30182. The first
compound identified, CCG-17950, inhibits the CDC25B-CDK2/Cyclin A interaction in vitro
with an IC50 of 6 µM by binding to the CDK2/Cyclin A complex. This compound also inhibits
CDK2dephosphorylationbyCDC25Binvitroand inpancreatic cancer cells. InhibitionofCDK2
dephosphorylationbyCCG-17950 in these cells led to cell cycle arrest andcell growth inhibition.
The second hit compound, CCG-18861, also inhibits the CDC25B-CDK2/Cyclin A interaction
in vitro by binding toCDK2/CyclinA,with an IC50 of 15 µM. Structural andmutagenesis studies
have indicated that CCG-18861 binds to the RxL-binding motif on Cyclin A, likely disrupting
the interaction with the CDC25B C-terminal tail. The third validated hit, CCG-42172, inhibited
theCDC25B-CDK2/CyclinA interactionwith an IC50 of 2 µM.NMRexperiments indicated that
this compound also binds to the CDK2/Cyclin A complex. The final hit identified was
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CCG-30182, which inhibited the CDC25B-CDK2/Cyclin A interaction with an IC50 of 11 µM.
However, its mechanism of action remains unclear.
In summary, we have developed a high quality HTRF assay for CDC25B-CDK2/Cyclin
A interaction that is both robust and sensitive, and highly suitable for screening large compound
libraries. Furthermore, theHTRF assay represents an example of a high quality “gray box” assay
which overcomes number of limitations of previously reported attempts to identify inhibitors of
CDC25 phosphatases. Despite the fact that we identified several small molecule inhibitors
blockingCDC25B-CDK2/CyclinA interaction, we have not found any compounds that directly
bind CDC25B. Identification of PPI inhibitors is challenging, in part due to lack of high quality
compound libraries optimized for targeting PPI interfaces32,33. The HTRF assay we developed
could be employed to screen more suitable focused libraries to identify inhibitors of CDC25B.
4.8 Experimental procedures
Expression and purification of recombinant CDC25B and CDK2/Cyclin A
All CDC25B and CDK2/Cyclin A proteins and their variants were expressed as described in
Chapters 1 and 2.
AlphaLISA HTS assays and the AlphaLISA counter screen
C-terminally 6xHis tagged CDK2/Cyclin A complex and N-terminally Flag tagged CDC25B
C473S (either 372-557 for the firstHTS,or372-566 for the rescreen)were expressedandpurified
as stated above. Proteins were incubated together at a final concentration of 300 nM each for 1
hr prior to incubation with compound for 1 hr, followed by addition of Ni-chelate AlphaScreen
donor beads (Perkin-Elmer) and Anti-Flag AlphaLISA acceptor beads (Perkin-Elmer) at a final
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concentration of 3 µg/mL for 1 hr. Assay reagents were dispensed using a multidrop liquid
dispenser (Thermo Scientific) onto uncoated, white, low-volume, 384-well plates (Corning).
AssayplateswerequantifiedusinganEnvisionplate reader (Perkin-Elmer)withexcitationat680
nm wavelength and emission at 615 nm in 9 µL volumes. Assays were performed in a buffer
containing 50 mMMOPS (pH 7.25), 50 mM NaCl, 1mM TCEP, with addition of 0.01% BSA,
and 0.01% Tween-20 immediately prior to the start of the assay.
The AlphaLISA assay used in HTS-2 was as described above except for the following
alterations.Final protein concentrationswere75nMeach, and finalAlpha reagent concentrations
were 0.5 µg/mL each. Assay volumes were 18 µL. The buffer described above for HTS-1 was
supplemented with 10mM MgCl2 and 1mM ATP.
TheAlphaLISA counter screening assays for bothHTS-1 and 2were performed as in the
HTS-1 and 2 primary assays without the CDK2/Cyclin A protein complex, and instead with a
His-GST-CDC25B-Flag protein.
Compound similarity clustering
Compounds were clustered by first splitting structures into Daylight-based substructure
fingerprints34. Compound daylight fingerprints were the compared using a variation of the
Tanimoto coefficient to calculate similarity35. Compounds with a Tanimoto coefficient greater
than 0.65 were clustered.
HTRF HTS assay
C-terminally 6xHis tagged CDK2/Cyclin A complex and N-terminally Flag tagged CDC25B
C473S (372-566) were expressed and purified as stated above. Proteins were incubated together
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at a final concentration of 125 nM each for 1 hr prior to incubation with compound for 1 hr,
followed by addition of anti-6xHis europium cryptate donor beads (Cisbio) and anti-Flag
XL-665 acceptor beads (Cisbio) at a final dilution of 1:350 for 1 hr. 20mM potassium fluoride
was added 10 minute prior to plate reading. Assay reagents were dispensed using a multidrop
liquid dispenser (Thermo Scientific) onto uncoated, black, low-volume, 384-well plates
(Corning). Assay plates were quantified using an Envision plate reader (Perkin-Elmer) with
excitation of the europium crytate donor at 337 nmwavelength and emission of the donor at 620
nm and emission of the XL-665 acceptor at 665 nm in 18 uL volumes. Assays were performed
in a buffer containing 50 mM Tris (pH 7.5), 50 mM NaCl, 10mM MgCl2, 1mM TCEP, with
addition of and 1mMATP, 0.05% BSA, and 0.05% Tween-20 immediately prior to the start of
the assay.
Compound libraries screened
The compounds tested for all high-throughput screening was from the library of the University
of Michigan Center for Chemical Genomics, and was comprised of a commercially available
subset of compounds from ChemDiv, Maybridge HitFinder, and Chembridge screening
libraries.
Ligand-detected NMR experiments
Samples for saturation transfer difference (STD) experiments were made with 2 µM CDK2/
Cyclin A or the CDK2/Cyclin A I213E mutant in 50 mM Tris (pH 8.0), 150 mM NaCl, 1 mM
β-mercaptoethanol, and 5% D2O. Compounds were tested at final concentrations of 150 µM in
5%DMSO.STDexperiments used 2 s irradiation using a train of 50msGaussian pulses centered
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at 0 ppm using a previously described pulse sequence36.
Samples for WaterLOGSY experiments were prepared as above with 2 µM CDK2/
Cyclin A and 150 µM compound. Pulse sequences used for WaterLOGSY experiments were as
previously described37. Water was inverted using a 10 ms Gaussian pulse followed by a 1.5 s
mixing time and a relaxation delay of 2 s.All spectrawere acquired at 25 °Con a 600MHzBruker
Avance III spectrometer equipped with cryoprobe, running Topspin version 2.1.
Crystallization and structure determination CDK2/Cyclin A with CCG-18861
Crystals of apo-CDK2/Cyclin A were produced as previously published25. After formation,
crystals were transferred to the mother liquor solution to containing either 5%DMSO control or
2mMCCG-18861 in5%DMSOand soaked for 4.5hours andwere then transferred to themother
liquor solution containing 5% DMSO control or 2 mM CCG-18861 in 5% DMSO, and 20%
glycerol for cryoprotection prior to freezing in liquid nitrogen. Diffraction data was collected at
the 21-ID-G beamline for the CCG-18861 complex and the 21-ID-D beamline for the DMSO
control at theLifeSciencesCollaborativeAccessTeamat theAdvancedPhotonSource.Thedata
was integrated and scaled using Mosflm38 and the structures were solved by molecular
replacement with MOLREP39 using the known apo-CDK2/Cyclin A structure for the search
model (PDB code: 4I3Z)40. Refinement for both structures was performed using REFMAC41,
COOT42, and the CCP4 program suite43 (Table 4.A3). The structure was validated using the
MOLPROBITY44 server.
In vitro CDC25B phosphatase activity assay
Western blot in vitro phosphatase activity assay was performed as described in Chapter 3.
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Cell culture and reagents
Human pancreatic carcinoma cell line MIA PaCa-2, were a generous gift from Dr. Mats
Ljungman. Cells were cultured in DMEM and supplemented with 10% fetal bovine serum and
1% antibiotics in a 5% CO2 humidified incubator at 37 °C.
MTT Assay
For cell viability experiments, 2.5   103 MIA PaCa-2 cells suspended in 100 µL growth media
were plated in quadruplicate on tissue culture treated clear, flat bottomed, cell culture-treated 96-
well plates. After 16 hours, mediawas aspirated and replaced bymedia containing either vehicle
control (0.25% DMSO) or compound (0.25% final DMSO concentration) and incubated for 72
hours. MTT labeling was done using the Vybrant MTT Cell Proliferation Assay Kit and
absorbance at 570 nm was read using a PheraStar plate reader.
Immunoblotting
MIA PaCa-2 cells for immunoblotting experiments were plated in a 6-well cell culture-treated
plate (2mL/well at 50,000 cells/mL) and synchronized at theG1/S phase transition using a double
thymidine block with two 17 hour 2 mM thymidine treatments and 9 hours between treatments.
Immediately after release of the block, cells were treated with either 0.25% DMSO control or
compound (0.25%finalDMSOconcentration) for 16hours, followedby lysiswithBC300buffer
(20mM Tris (pH8.0), 300mM KCl, 1mM EDTA, 200 µM Na3VO4, 10% glycerol and 0.1%
NP-40 added fresh prior to lysis). Samples were separated on a 4-20%SDS-PAGE gel 170 volts
for 45 minutes. Proteins were transferred to nitrocellulose with a wet electrotransfer system
(BioRad) for 60 min at 25 volts. Following transfer, the membrane was blocked with 5% BSA
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in Tris-buffered salinewith 0.1%Tween-20 (TBS-T), and incubated overnight at 4 °Cwith anti-
pT15-cdc2 monoclonal antibody (#9111, Cell Signaling Technology, 1:2000). After washing,
the membrane was incubated with an HRP conjugated anti-rabbit antibody (1:10,000) and
visualized using enhanced chemiluminescence. Blots were then stripped and reblotted for total
CDK2 with an anti-cdk2 polyclonal antibody (sc-163, Santa Cruz Biotechnology, 1:5000)
followed by secondary antibody incubation and visualization as above.
Cell cycle analysis
For cell cycle analysis experiments, 2 mL MIA PaCa-2 cells (5.0 ✕ 104 cells/mL) were plated
on a 6-well culture treated plate and synchronized as described above. Cells were treated with
0.25%DMSOcontrol or compound in 0.25%DMSO for 16 hours. Each samplewas trypsinized,
washedwithPBS, and fixed in 70%ethanol. Sampleswere then treatedwithRNaseAand stained
with propidium iodide. 30,000 events were collected using a BD LSR II flow cytometer (BD
Biosciences), and analysis of the cell cycle distribution was performed using the BDFACSDiva
software (BD Biosciences).
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4.9 Appendices
Appendix Table 4.A1. Protein constructs used for high-throughput screening.Table #. Protein constructs 
!  
Construct name N-terminal tag Protein C-terminal tag 
HTS-1    
CDC25B-Flag -- CDC25B (372-557) Flag 
His-CDK2/Cyclin A 6xHis CDK2 (1-296)/ Cyclin A (173-432) -- 
His-CDC25B-Flag 6xHis CDC25B (372-557) Flag 
HTS-2    
CDC25B_long-Flag -- CDC25B (372-566) Flag 
His-CDK2/Cyclin A 6xHis CDK2 (1-296)/ Cyclin A (173-432) -- 
His-CDC25B_long-Flag 6xHis CDC25B (372-566) Flag 
HTS-3    
Flag-CDC25B_long Flag CDC25B (372-566) -- 
CDK2-His/Cyclin A -- CDK2 (1-296)/ Cyclin A (173-432) 6xHis 
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Appendix Table 4.A2. Hit selection process for HTS-2 confirmation screening. Hits from
the HTS-2 primary screen were selected by the categories shown below. Compounds were
were selected for confirmation screening based on 4 factors: their percent inhibition in
HTS-1, their percent inhibition in HTS-2, the difference in percent inhibition between HTS-1
and HTS-2, and the molecular weight of the compound. Group 1 represents hits that were
inactive in HTS-1 but active in HTS-2. Group 2 contains hits that were highly active in
HTS-1 and also active in HTS-2. Group 3 contains hits that were active in both HTS-1 and
HTS-2, but were at least 10% more active in HTS-2. Group 4 contains hits that were not hits
in HTS-1 and were weak in HTS-2, but were of low molecular weight.
Table #. Hit selection process for HTS-2 
  
Group HTS-1 (%) HTS-2 (%) HTS-1 – HTS-2 (%) 
Molecular 
weight (g/mol) 
Number of 
compounds 
selected 
1 < 30 > 30 > 5 -- 739 
2 > 75 > 30 -- -- 9 
3 > 30 > 30 > 10 -- 47 
4 -- 15 – 30 > 5 < 350 605 
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Appendix Table 4.A3. Crystallographic data collection and refinement statistics.!
PDB code CDK2/Cyclin A w/ CCG-18861 CDK2/Cyclin A w/ DMSO 
Data collection   
Space group  C 2 2 21 P 1 21 1 
Cell dimensions   
    a, b, c (Å) 72.3, 146.0, 163.3 70.0, 163.4, 73.1 
Resolution (Å) 2.60 (2.64-2.60) 2.20 (2.25-2.20) 
Unique reflections 27138 (1332) 77430 (4565) 
Rsym  0.427 (0.068) 0.684 (0.109) 
I / σI 13.3 (2.3) 15.4 (2.8) 
Completeness (%) 99.8 (99.3) 98.4 (87.5) 
Redundancy 6.2 (5.2) 3.7 (3.3) 
   
Refinement   
Rwork / Rfree (%) 20.7 / 25.0 21.3 / 25.1 
No. atoms   
    Protein 4427 8894 
    Water 0 0 
Mean B-factors (Å2) 34.17 37.8 
R.m.s. deviations   
    Bond lengths (Å) 0.008 0.019 
    Bond angles (°) 1.144 0.919 
Ramachandran plot   
Most favored regions 
(%) 
95.4 97.1 
Additional allowed 
regions (%) 
4.05 2.26 
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Chapter 5
Conclusions and future directions
5.1 Conclusions
The work in this dissertation describes our efforts to employ new approaches to target and
identify small molecule inhibitors of the CDC25B phosphatase. We have characterized the
structure and dynamics of CDC25B in solution and characterized its interactionwith the CDK2/
Cyclin A complex. In addition to the CDC25B-CDK2/Cyclin A interaction, we have
characterized the novel interaction between the DNA damage repair protein Mre11 and the
CDK2/Cyclin A complex. We have demonstrated that Mre11 interacts with CDK2/Cyclin A
through two motifs in the unstructured C-terminus, and that this interaction is at least in part
mediated through the RxL peptide binding site on Cyclin A. As discussed in Chapter 2, several
CDK2/CyclinAbinding partners have a similarmechanismof binding.An intriguing possibility
is that the MRE11 C-terminus competes with the CDK2 inhibitor protein p27 for binding to
CDK2/Cyclin A. The p27 protein binds primarily in three sites, the Cyclin A RxL-binding site,
the CDK2 regulatory site on the N-terminal lobe, and the CDK2 active site.Mutagenesis studies
have indicated that the first two sites are the primary mediators of the p27-CDK2/Cyclin A
interaction, while the very C-terminus of p27 blocks the active site1,2. The Mre11 C-terminus
interacts at least in part through the RxL-binding site, and the length of the linker between the
twobindingmotifs onMre11 is very similar to that of the p27protein. This leads to the possibility
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that Mre11 and p27 bind in a similar manner to CDK2/Cyclin A. The intriguing difference
between the Mre11 C-terminus and the p27 C-terminus is that the Mre11 C-terminus is much
shorter than that of p27, which would prevent it from being able to reach the CDK2 active site.
This may enableMre11 to compete with p27 for CDK2/Cyclin A binding without inhibiting the
CDK2/CyclinA active site. In an experimental observation not described in this thesis, we found
that Mre11 does not directly stimulate CDK2 kinase activity in vitro. The Mre11-p27
competition model may be a possible explanation for this observation. However, this model is
not fully consistent, as the p27-CDK2/Cyclin A interaction affinity is much stronger than the
affinity of the Mre11-CDK2/Cyclin A interaction3. This implies that if the Mre11-p27
competition model is correct, other factors must play a role.
In our efforts to develop novel small molecule inhibitors of CDC25B, we took a multi-
faceted drug discovery approach. We simultaneously explored two directions: fragment-based
drug discovery and high-throughput screening targeting the CDC25B-CDK2/Cyclin A protein-
protein interaction.UsingNMR-based fragment based screening,we identified a smallmolecule
ligand of the CDC25B catalytic domain. Additionally, we were able to solve the co-crystal
structure with our ligand bound to CDC25B. Guided by this structure, we designed a compound
with increased binding affinity by replacing an arginine-coordinated sulfate found in the
fragment binding site with a sulfonic acid linked to our ligand. We demonstrated that this
compoundwith increasedbindingaffinitydisrupts theCDC25B-CDK2/CyclinA interactionand
inhibits CDC25B catalytic activity. To our knowledge, our inhibitor-bound crystal structure of
CDC25B is the first crystal structure with CDC25B bound to a small molecule ligand. This, in
combinationwith our characterization ofCDC25B in solution, rationalizes the use of a structure-
guided small molecule design approach.
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In addition to its advancement of CDC25B inhibitor development, our fragment-based
drug discovery (FBDD) efforts help validate the use of this approach to inhibit other difficult but
important drug targets. There have been many important targets that have proven difficult for
inhibitor discovery using traditional approaches. Studies employing FBDD have had some
success in developing inhibitors of such proteins. One recent example of this was the use of
FBDD to develop inhibitors of K-Ras4, a well-established target for therapeutic intervention in
a wide variety of cancers that has resisted inhibitor development for many years. Our fragment-
based drug discovery study targeting CDC25B adds evidence to the hypothesis that the FBDD
may be a more attractive approach to target proteins that have been difficult to inhibit using
traditional drug discovery approaches.
In addition to fragment based drug design, we have developed PPI assays to quantify the
interaction betweenCDC25B andCDK2/CyclinA.We employed these assays inmultiple high-
throughput screens to identify several new classes of CDC25B-CDK2/Cyclin A protein-protein
interaction inhibitors. These compounds have shown promising activities in our initial
characterization. Importantly, we have developed a high quality screening assay system for
targeting this interaction by using an HTRF-based primary screen and an AlphaLISA-based
counter screen. This approach will be useful for future drug discovery efforts.
Despite the development of a high-quality screening assay, we have been unable to
identify compounds directly inhibitingCDC25B in our high-throughput screens.We know from
our fragment-based screening approach that inhibitors targeting CDC25B can be developed;
however, no compound identified by high-throughput screening interactswithCDC25B.All the
validated inhibitors we identified in our three high-throughput screening campaigns bind to
CDK2/Cyclin A. A possible reason for the lack of direct CDC25B inhibitors identified relates
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to the compound libraries we screened. Many compound screening libraries are not well suited
for the discovery of protein-protein interaction inhibitors5,6, so it is possible that the libraries we
screened simply do not contain the type of compounds that bind toCDC25B.As focused protein-
protein interaction inhibitor libraries becomemoreprominent, our assaywill be useful for further
screening efforts targeting CDC25B.
In addition to the CDC25 family of phosphatases, other dual specificity phosphatases
(DSPs) have been implicated in a variety of human diseases7,8. Several of these DSPs have been
shown to have therapeutic potential in and cancer and other diseases8. However, like the CDC25
family, the DSPs superfamily in general have proven to be difficult drug targets due to their
shallow active sites and complex substrate recruitment mechanisms8. The approaches described
here, including fragment-based drug discovery and protein-protein interaction based high
throughput screening, may be an attractive approach to target other members of the DSP
superfamily. The validity of this approach has been recently corroborated in a study where
protein-protein interaction based high throughput screening led to the identification of an
allosteric inhibitor of the oncogenic DSP Wip19. The studies described in this dissertation add
to the growing knowledge of how inhibitors of this important class of enzymes can be identified
and developed.
5.2 Future directions
The conclusions of this dissertation open several new lines of inquiry. Regarding the Mre11-
CDK2/Cyclin A interaction: we have identified the motifs through which this interaction is
mediated, but how Mre11 activates the CDK2/Cyclin A complex remains unknown. As
hypothesized above, the increased kinase activity of CDK2 may be due to competition with the
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CDK2/Cyclin A inhibitor p27. Multiple approaches could be taken to evaluate this hypothesis.
Structural studies of the Mre11-CDK2/Cyclin A complex would reveal if there is similarity
between the Mre11 and p27 binding modes. This hypothesis could be further assessed in vitro
by determiningMre11-p27 competition for CDK2/Cyclin A binding. However, this approach is
limited due to the higher affinity of p27 for CDK2/Cyclin A in vitro. This model may be better
addressed in cells by overexpressing the Mre11 C-terminus and looking into the extent of p27-
CDK2/Cyclin A interaction by co-immunoprecipitation. In addition to themechanism of CDK2
activation, the regulation mode of the Mre11-CDK2/Cyclin A interaction remains unknown.
Further biological studies will be required to determine the pathways and mechanisms involved
in regulating this interaction in cells.
Regarding the development of CDC25B inhibitors: as mentioned above, our structure of
the CDC25B-inhibitor complex is the first such structure published, and our studies have
indicated that this site is amenable to structure-based design. Further development of our
fragment-derived inhibitor will require involvement of medicinal chemistry in order to develop
more potent compounds. Several additional approaches for enhancing the binding affinity could
be tried. For example, replacing one or more of the water molecules found near the hydroxyl
group of the compound might increase the binding affinity of our inhibitor. Additionally,
modification at the 5-position on the benzene ring may form additional contacts with the
backbone amide of glycine 80 or the side chain of arginine 488. Further chemical exploration of
this molecule may lead to more potent inhibitors.
The development of our high-throughput screening assays targeting the CDC25B-
CDK2/Cyclin A interaction and the compounds they identified both warrant further study.
Further experimentation with our lead compounds can be done to further explain their
133
mechanism of action and improve their potency. We have shown by NMR that CCG-17950
interacts with the CDK2/Cyclin A complex, but its mode of action is unclear. The presence of
either ATP or a potent ATP-competitive inhibitor does not affect the inhibitory activity of
CCG-17950, so it unlikely to bind in the CDK2 active site. Structural studies have proven
difficult due to the low solubility of the compound. The number of available commercial analogs
of CCG-17950 is very limited, so analogs with increased potency and/or solubility would need
to be synthesized. Such analogs may be more amenable to structural characterization. As with
CCG-17950, relatively few analogs of CCG-18861 are commercially available, and of those we
were able to obtain, none had an increased potency compared to the original compound. If more
potent analogs of CCG-18861 can be developed, these may allow for the determination of a
inhibitor-bound co-crystal structure with CDK2/Cyclin A. A co-crystal structure with a
CCG-18861 analog would help us better understand its mechanism of inhibition in the context
of the Cyclin A RxL-binding pocket. Such information would allow for structure-guided drug
design of increasinglymore potent analogs of CCG-18861. In addition to structural information,
more potent CCG-18861 analogs would allow for characterization of the cellular activities of
these inhibitors. The RxL-binding site on cyclins is an important structural feature, mediating
interactions with a number of substrates, protein activators, and protein inhibitors. A cell-active
inhibitor of this sitewouldbeuseful in characterizing thebiological role of this site.Additionally,
this sitemay represent a new approach to targetingCDKactivity by disrupting cyclin-dependent
substrate recruitment. The RxL-binding site has been targeted previously with peptide-based
inhibitors10–12, but converting thesemolecules into lead compounds remains a challenge13,14. Our
inhibitor may provide a new scaffold for targeting this site.
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Importantly, our high-throughput screening assays allow for the discovery of additional
inhibitors of the CDC25B-CDK2/Cyclin A interaction. Our HTRF-based high-throughput
screening assay is both robust and sensitive, and uses an entirely different approach to previous
high-throughput screens targeting CDC25B. The low hit rate we observed indicates that this
assay could be used to potentially screen very large compound libraries while still being able to
follow upwithweak hits. Our assay could also be used to screen compound libraries specifically
designed for the discovery of PPIs, which may be better suited for finding inhibitors of the
CDC25B-CDK2/Cyclin A interaction.
5.3 Final remarks
In all, the work presented in this dissertation describes several new approaches to inhibit
CDC25B that have not been tried in over 20 years of targeting the CDC25 family. We have laid
the groundwork for the identification and development of novel chemical probes and potential
therapeutic agents targeting CDC25B.
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Chapter 6
Appendix - development of the FMAP program for use in the rational design of
fluorinated compounds
6.1 Abstract
Multipolar interactions involving fluorine and the protein backbone have been frequently
observed in protein-ligand complexes. Such fluorine-backbone interactions may substantially
contribute to high affinity binding of small molecule inhibitors. In order to facilitate the design
of multipolar fluorine-backbone interactions in protein-ligand complexes we developed a
computational algorithm named FMAP,which calculates fluorophilic sites in close proximity to
protein backbone. We demonstrated that FMAP could be used to rationalize improvement in
activity of knownprotein inhibitors upon introduction of fluorine. Furthermore, FMAPmay also
represent avaluable tool fordesigningnewfluorine substitutionsandsupport ligandoptimization
in drug discovery projects.
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6.2 Rationale and implementation of FMAP
The primary impetus for developing the FMAP program was the observation of large gains in
affinity upon the introduction of specifically placed fluorine atoms in our thienopyrimidine class
of menin inhibitors. Substitution of a propyl group on the thienopyrimidine scaffold with
trifluoroethyl resulted in a 10-fold increase in the binding affinity1. The crystal structure of this
compound bound to menin revealed that the CF3 group is involved in close contacts with the
protein backbone. This kind of C–F···C=O orthogonal interaction had also been previously
reported in the literature as an effective method for increasing binding ligand binding affinity2–
4.Beyond the increase inbindingaffinity, introductionof fluorine atoms intodrug-likemolecules
can improve their physiochemical properties5. However, introduction of fluorine atoms into
ligand molecules might be synthetically challenging or may require multi-step synthesis.
Therefore, we wanted to develop a method for rational design of favorable fluorine interactions
in protein-ligand complexes that would significantly accelerate inhibitor development in our
drug discovery projects. We designed the FMAP program to predict regions of the protein
backbone that are reasonably exposed in order to engineer favorable C–F···C=O interactions.
FMAP is implemented in python, and can be run either as a pymol extension or as a standalone
command-line program. FMAP requires the Biopython module6,7.
6.3 PDB search for fluorine containing protein-ligand complexes
To get an idea for the geometrical criteria of the C–F···C=O interaction, I performed a search of
thePDB to identify protein-ligandcomplexes containing fluorine atoms. I identified2559crystal
structures containing a fluorinated ligand and performed an analysis using a python script to
select structures in which a fluorine atom is located within 3.5 Å of either the peptide backbone
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carbonyl carbonor amidenitrogen. I accepted structureswith2.2Åresolutionorbetter for further
analysis. I found total of 442 protein-ligand complexes fitting these criteria for detailed analysis.
Thegeometrical positionof each fluorine in thesecomplexeswith respect to theproteinbackbone
was extracted and mapped onto an example protein residue (Figure 6.1). This search
demonstrated that fluorine is frequently located within a short distance of protein backbone, and
exemplifies thepresenceofmultipolarC–F···C=Ointeractionsdescribed indetail in theprevious
studies3,4.
6.4 Hypothetical fluorine position calculation by FMAP
Calculation of the fluorine sites is initiated by defining an arbitrary number of 29 hypothetical
fluorine positions within 3 Å distance from either the backbone carbon or nitrogen. These
hypothetical fluorine positions are based on my analysis of protein-ligand complexes from the
PDB; I selectedgeometric criteria to encompass~80%of fluorine sites found in this analysis.The
hypothetical fluorine positions are defined in spherical coordinates from either the carbonyl
carbon or the amide nitrogen in a right-handed spherical coordinate system. The corresponding
Cartesian coordinate system to the spherical coordinate system is defined by the positive Z-axis
(zenith reference) along the C=O bond, the positive X-axis (azimuth reference) perpendicular to
the Z-axis in the peptide bond plane in the direction of the amide bond, and the Y-axis
perpendicular to the peptide plane. The same coordinate system axes is used for all hypothetical
positions, however 11 of the hypothetical fluorine positions use the carbonyl carbon as the origin
and the remaining positions use the amide nitrogen. The spherical coordinates of the 29
hypothetical fluorine positions and their reference atom are given below (Table 6.A1).Mapping
of these hypothetical positions to a hypothetical peptide bond along with the fluorine positions
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from my PDB analysis is shown in Figure 6.1.
The 29 hypothetical fluorine positions are then calculated for every residue in the protein
of interest. This is accomplished by a translation of the origin followed by a quaternion rotation
to align the coordinate system of the hypothetical peptide bond and the coordinate system of a
given residue. This allows each hypothetical fluorine position to be calculated for any given
residue. This process is applied iteratively for all residues in the protein. Once the complete set
of hypothetical positions is calculated for the entire protein, unlikely positions are removedusing
a series of filters.
Figure 6.1. PDB analysis and prediction of favorable C–F···C=O interactions using FMAP
algorithm. Combined analysis of protein-ligand structures from PDB, with FMAP
predictions of the potential fluorine positions and their representative C-F bonds relative to
backbone peptide bond. Positions of fluorine atoms derived from the protein-ligand
complexes found in PDB are shown as cyan points. FMAP prediction is shown as purple
surface with orange vectors shown for representative C-F bonds.
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6.5 FMAP fluorine position filtering criteria
FMAP eliminates unlikely fluorine positions through filters based on unfavorable geometry for
multipolar interactions as well as steric clashes with protein atoms. This series of filters is
comprised of the following criteria: 1) steric clash; fluorineswithin 1.8Åof any protein atom are
removed. 2) entirely buried or overly exposed fluorines; this filter removes positions that are not
accessible to small molecules or are entirely exposed, such as protein termini, loops; this is
accomplished through a summation the number of Cαs closer than 10 Å and the number of total
atoms closer than 5 Å; any position with a Cα count between 15-28 and a total atom count less
than 30 is retained. 3) fluorines too close to carbonyl oxygens; positions are eliminated when
closer than 2.7 Å from a carbonyl oxygen and less than 60 degrees off the C=O bond vector,
eliminating positions that are too close to the electron lone pairs of carbonyl oxygens. 4) isolated
sites; this procedure eliminates isolated fluorines, removing positions that are not clustered with
other nearby fluorines; fluorines with less than 5 adjacent fluorines within 3.2 Å are removed.
A second, more restricted set of fluorine positions is also defined by FMAP. These
positions are a subset of the previously defined positions, and are limited to positions further than
2.7 Å away from another atom, and 3.0 Å away from a carbonyl oxygen for positions less than
60 degrees off the C-O bond vector.
6.6 FMAP visualization in Pymol
Fluorine positions retained after the filtering process are visualized using aPymol8 extension and
are represented as a surface spanning 2.8-3.2 Å range from the peptide bond (Figure 6.1). This
allows for a clear representation of favorable sites for forming aC–F···C=O interaction. The less
restricted positions are shown in purple and the more restricted positions are shown in orange.
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6.7 Training and application of FMAP
As the primary impetus for developing FMAP was to predict sites similar to those contributing
to the affinity gains observed for our fluorinated menin inhibitors, I used these structures as
trainingstructures for theprogram.The favorable sitespredictedby the finalversionof theFMAP
program agreed well with the C–F···C=O interactions observed in the menin-inhibitor crystal
structure (Figure 6.2). Once the program was fully developed and trained on these structures, it
was tested against a set of protein-ligand structures with ligands for which the activity of
unsubstituted and fluorine substituted analogs have been determined and the crystal structures
of fluorine analogs bound to the target proteins are available.
Several structures were selected for FMAP analysis to rationalize fluorine substitutions
in these known ligands. FMAPwas used to analyze the protein-ligand structures of the following
inhibitors inwhich the addition of fluorine led to an increase in ligand potency: the tricyclic class
of thrombin inhibitors9, fragment-based inhibitors of procaspace-610, the tetramethylpiperidine
class of HIV viral envelope glycoprotein gp120 inhibitors11, and β-lactamase inhibitors12. The
FMAP predictions for these protein-ligand structures agreed well with the increase in potency
by the introduction of fluorine in each of the inhibitors (Figure 6.3).
Figure 6.2. FMAP prediction for the
menin-MI-2-3 complex. Purple
surface represents favorable positions
for fluorine atoms to interact with
protein backbone as predicted by
FMAP.
142
There were several examples found where substitution with fluorine did not have
beneficial effect on inhibitory activity despite reasonably good agreement with the FMAP
predictions. In two examples, introduction of fluorine into inhibitors of neuronal nitric oxide
synthase13 and c-Jun N-terminal kinase 114 led to the modest decrease in the inhibitory activity.
This indicates that prediction of fluorine substitutions based solely on geometrical criteriamight
have potential limitations and other factors such as effect of fluorine on stereoelectronic or
conformational properties of the ligand, or structural changes upon ligand binding might need
to be considered in order to further improve the design of C–F···C=O interactions.
Figure 6.3. Analysis of FMAP calculations for known inhibitors containing fluorine atoms.
Crystal structure of protein-inhibitor complexes showing close C–F···C=O contacts and FMAP
predictions (in purple). The structures of inhibitors and activities are also reported. a) thrombin
inhibitor (PDB code 1OYT). b) procaspase-6 inhibitor (PDB code 4NBL). c) gp120 inhibitor
(PDBcode 4DKO), d)β-lactamase inhibitor (PDBcode 4E3N). Figure produced by JonPollock.
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6.8 Conclusions
The FMAP program was developed to facilitate the rational design of C–F···C=O interactions
inprotein-ligandcomplexes. FMAPuses aprotein crystal structure andcalculates sites that could
be favorable for forming C–F···C=O ligand-protein interactions. We demonstrated that FMAP
could be used to rationalize the improvement in activity of several known inhibitors upon
introduction of fluorine. FMAPmay also represent a valuable tool for the design of new fluorine
substitutions in protein ligands. FMAP relies solely on geometrical and structural criteria, and
other effects, such as conformational or electronic changes resulting from fluorine substitution
are not taken into account, whichmight represent a limitation of this approach. Nevertheless, we
expect the FMAP can be very useful in the drug discovery projects to rationally design new
fluorinated ligands. The predictive power of FMAP in the rational design of fluorinated ligands
is currently being explored in several projects in the Cierpicki and Grembecka laboratories.
Notes
This appendix is based on amanuscript in preparation “Rational design of orthogonalmultipolar
interactions with fluorine in protein-ligand complexes” by Jonathan Pollock, Dmitry Borkin,
George Lund, Trupta Purohit, Edyta Dyguda-Kazimierowicz, Jolanta Grembecka and Tomasz
Cierpicki. Jonathan Pollock performed an extensive literature review regarding the role of
fluorines in ligand-protein interactions, determined all menin-inhibitor complex structures and
prepared the majority of the manuscript and figures; Dmitry Borkin also contributed to the
literature review andwas responsible for themenin inhibitor design and synthesis; George Lund
performed the analysis of the PDB structures containing C–F···C=O interactions, wrote the
FMAP program and wrote the description of the algorithm; Trupta Purohit performed activity
fluorescence polarization assays for determination of the potency of menin-MLL inhibitors;
Edyta Dyguda-Kazimierowicz performed quantum mechanical calculations of the C–F···C=O
interaction (not shown here); , Jolanta Grembecka and Tomasz Cierpicki supervised the project
and reviewed the manuscript.
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Hypothetical fluorine Reference atom R (Å) Polar angle (rad) Azimuthal angle (rad) 
1 C 3.00 1.47 1.57 
2 C 3.00 1.89 1.71 
3 C 3.00 1.31 1.14 
4 C 3.00 0.97 1.50 
5 C 3.00 1.20 1.90 
6 C 3.00 1.60 1.97 
7 C 3.00 1.53 -1.33 
8 C 3.00 1.14 -1.48 
9 C 3.00 1.87 -1.70 
10 C 3.00 1.20 -0.91 
11 C 3.00 1.47 -1.84 
12 N 3.00 1.33 1.31 
13 N 3.00 1.55 1.67 
14 N 3.00 1.89 1.82 
15 N 3.00 2.18 2.12 
16 N 3.00 2.31 1.22 
17 N 3.00 2.36 1.72 
18 N 3.00 1.92 1.52 
19 N 3.00 2.00 1.14 
20 N 3.00 1.58 1.07 
21 N 3.00 1.72 -1.51 
22 N 3.00 2.02 -1.91 
23 N 3.00 1.31 -1.15 
24 N 3.00 1.82 -0.91 
25 N 3.00 2.21 -0.82 
26 N 3.00 2.52 -1.05 
27 N 3.00 2.14 -1.26 
28 N 3.00 2.40 -1.75 
29 N 3.00 2.81 -1.60 
6.9 Appendices
Appendix Table 6.A1. Polar coordinates of the hypothetical fluorine positions and their
reference atom.
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